

Acne Medications:			
<u>Oral</u>	3		
<u>Topical-Anti-infectives</u>	4		
<u>Topical-Retinoids</u>	5		
<u>Topical-Rosacea</u>	5		
Alzheimer's Medications:			
<u>Cholinesterase Inhibitors/NMDA</u>			
<u>Receptor Antagonists</u>	5		
Analgesics:			
<u>COX-2 Inhibitors</u>	6		
<u>Local Anesthetics: Transdermal Patch</u>	6		
<u>Narcotics-Short Acting</u>	6-7		
<u>Narcotics-Long Acting</u>	7		
<u>NSAIDS</u>	8		
Anemia Medications:			
<u>Hematopoietic/Erythropoietic Agents</u>	8		
Ankylosing Spondylitis Injectables	8		
Anti-anxiety: <u>Anxiolytics</u>	9		
Anticoagulants	9		
Anticonvulsants	10		
Anti-depressants:			
<u>Miscellaneous</u>	10		
<u>SNRIs</u>	11		
<u>SSRIs</u>	11		
<u>Tricyclics</u>	12		
<u>MAO Inhibitors</u>	12		
Anti-diabetics:			
<u>Alpha Glucosidase Inhibitors</u>	12		
<u>Biguanides & Combinations</u>	12		
<u>Peptide Hormones</u>	12		
<u>Insulin</u>	13		
<u>Oral-Meglitinides</u>	13		
<u>Sulfonylureas 2nd Generation</u>	13		
<u>Thiazolidinediones & Combinations</u>	14		
<u>Dipeptidyl Peptidase Inhibitors</u>	14		
Anti-emetics:			
<u>NK1/5HT3 Antagonists</u>	14		
<u>Other</u>	14		
Anti-hyperkinesia and Anti-Narcolepsy:			
<u>Short/Intermediate-Acting MPH</u>	15		
<u>Long-Acting MPH</u>	15		
<u>Short/Intermed-Acting Amphetamines</u>	15		
<u>Long-Acting Amphetamines</u>	15		
<u>Non-Stimulants Products</u>	15		
<u>Xyrem</u>	15		
Anti-hypertensives:			
<u>ACE Inhibitors</u>	15		
<u>ACEI with Hydrochlorothiazide</u>	16		
<u>ACE Inhibitors with CCBs</u>	16		
<u>Angiotensin Receptor Blockers</u>	16		
<u>ARBs/Hydrochlorothiazide Combos</u>	16		
<u>ARBs/CCB Combos</u>	16		
<u>Beta-Blockers</u>	17		
<u>Calcium Channel Blockers</u>	17		
<u>Renin Inhibitors</u>	18		
Anti-infectives:			
<u>Cephalosporins: 1st Generation</u>	18		
<u>Cephalosporins: 2nd Generation</u>	18		
<u>Cephalosporins: 3rd Generation</u>	18		
<u>Ketolides</u>	18		
<u>Macrolides</u>	19		
<u>Oxazolidinones</u>	19		
<u>Penicillins (Oral)</u>	19		
<u>Quinolones</u>	19		
<u>Antifungal: Allylamines</u>	20		
<u>Antifungal: Azoles</u>	20		
<u>Antifungal: Topical: Onychomycosis</u>	20		
<u>Anti-virals: Herpes (Oral)</u>	20		
<u>Influenza Medications</u>	20		
<u>Influenza Vaccines</u>	21		
<u>Miscellaneous</u>	21		
<u>Topical Antibiotics</u>	21		
Anti-migraine: <u>Triptans</u>	21		
Anti-obesity	22		
Anti-psychotic:			
<u>Atypicals & Combinations</u>	23		
<u>Typicals</u>	24		
Botulinum Toxins	24		
BPH:			
<u>Alpha Blockers</u>	24		
<u>Androgen Hormone Inhibitors</u>	24		
Cardiac Glycosides	24		
Chemical Dependency	25		
Constipation: Chronic or IBS-C	25		
Contraceptives: <u>Vaginal Ring</u>	25		
Coronary Vasodilators/Antianginals:			
<u>Oral</u>	25		
<u>Topical</u>	26		
Cough and Cold Preparations	26		
Dermatological Agents:			
<u>Genital Wart Therapy</u>	26		
<u>Scabicides and Pediculicides</u>	26		
Desmopressin: Intranasal	26		
Diabetic Testing Supplies	27		
Gastrointestinals:			
<u>Crohn's Disease Injectables</u>	27		
<u>H2-blockers</u>	27		
<u>Inflammatory Bowel (Oral/Rectal)</u>	28		
<u>Proton Pump Inhibitors</u>	28		
<u>Ulcerative Colitis Injectables</u>	28		
Glucocorticoids: <u>Topical</u>	29		
Growth Stimulating Agents	30		
Hemophilia Factors	30		
Hepatitis C Agents	30		
Immunomodulators: <u>Topical</u>	30		
Lipotropics:			
<u>Bile Acid Sequestrants</u>	31		
<u>Fibric Acid Derivatives</u>	31		
<u>Niacin Derivatives</u>	31		
<u>Statins</u>	31		
<u>Miscellaneous/Combinations</u>	32		
Miscellaneous			
<u>Arcalyst® (CAPS Injectable)</u>	32		
<u>Elaprase® (Hunter's Syndrome</u>			
<u>Injectable)</u>	32		
<u>Soliris® (Paroxysmal Nocturnal</u>			
<u>Hemoglobinuria Injectable)</u>	32		
<u>Somatuline® (Acromegaly Injectable)</u>	32		
Mood Stabilizers	32		
Multiple Sclerosis: <u>Injectables</u>	33		
Nutritionals, enteral	33		
Ophthalmics:			
<u>Antihistamines</u>	33		
<u>Glaucoma Agents/Miotics</u>	34		
<u>Mast Cell Stabilizers</u>	34		
<u>NSAIDS</u>	34		
<u>Quinolone Anti-infectives</u>	35		
Ossification Enhancers	35		
Otic: Anti-infectives	35		
Parkinson's Treatments:			
<u>Dopamine Agonists</u>	36		
Phosphodiesterase-5 Inhibitors	36		
Platelet Inhibitors	36		
Psoriasis Injectables	37		
Psoriasis Non-biologics	37		
Pulmonary:			
<u>Anticholinergics, Inhaled</u>	37		
<u>Antihistamines -Intranasal</u>	37		
<u>Antihistamines -1st Generation</u>	38		
<u>Antihistamines - 2nd Generation</u>	38		
<u>Persistent Asthma: Xolair®</u>	38		
<u>Beta-adrenergic Agents</u>	39		
<u>Inhaled Glucocorticoids</u>	40		
<u>Nasal Glucocorticoids</u>	40		
<u>Systemic Glucocorticoids</u>	40		
<u>Leukotriene Modifiers</u>	41		
<u>RSV Prevention: Synagis®</u>	41		
Renal Disease: <u>Phosphate Binders</u>	41		
Rheumatoid and Psoriatic Arthritis:			
<u>Immunomodulators</u>	41		
Saliva Stimulants	41		
Sedative/Hypnotics	42		
Skeletal Muscle Relaxants: <u>Oral</u>	42		
Smoking Cessation Therapies	43		
Testosterone: <u>Topical</u>	43		
Urinary Antispasmodics	44		
Vaginal: <u>Anti-infectives</u>	44		
Vitamins: <u>Prenatal Multivitamins</u>	44		

Phone Numbers for Vermont Medicaid PBM Program

MedMetrics Health Partners (MHP)

PRESCRIBER Call Center:

PA Requests

Tel: 1-800-918-7549; Fax: 1-866-767-2649

Note: Fax requests are responded to within 24 hrs.

For urgent requests, please call MHP directly.

MHP Clinical Staff:

Diane Neal, RPh (o): 802-879-5605

(f): 802-879-5919

E-mail: diane_neal@medmetricshp.com

OVHA Medical Staff:

Associate Medical Director

Erin Cody, M.D., (o) 802-879-5920;

(f) 802-879-5963

MedMetrics Health Partners (MHP)

PHARMACY Call Center:

Tel: 1-800-918-7545

Available for assistance with claims processing

MHP Program Rep-Vermont:

Assistance with any issues related to the PBM program.

Nancy Miner, CPhT, (o) 802-879-5638

(f): 802-879-5919

E-mail: nancy_miner@medmetricshp.com

OVHA Pharmacy Unit Staff:

Stacey Baker, (o) 802-879-5912;

(f) 802-879-5919

E-mail: Stacey.Baker@ahs.state.vt.us

MHP Account Manager:

Nancy Hogue, Pharm.D., (o): 802-879-5604

(f): 802-879-5919

E-mail: nancy_hogue@medmetricshp.com

Acne Drugs: Oral
Length of Authorization: 1 year

NO PA REQUIRED

DOXYCYCLINE† 20 mg, 50 mg, 75 mg, 100 mg, 25 mg/5 ml
tab, cap, susp

ERY-TAB® (erythromycin base, delayed release)
ERYTHROCIN† (erythromycin stearate)
ERYTHROMYCIN BASE†
ERYTHROMYCIN ESTOLATE†
ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S.®,
Eryped®)
ERYTHROMYCIN STEARATE†

MINOCYCLINE† 50 mg, 75 mg, 100 mg

TETRACYCLINE† 250 mg, 500 mg cap

ISOTRETINOIN† 10 mg, 20 mg, 40 mg cap (SOTRET,
CLARAVIS, AMNESTEEM)

PA REQUIRED

Adoxa®* (doxycycline monohydrate) 50 mg, 75 mg tab, 100 mg tab, 150 mg
tab
Adoxa Pak®* (doxycycline monohydrate) 1/75 mg, 1/100 mg, 1/150 mg,
2/100 mg
Doryx®* (doxycycline hyclate) 75 mg, 100 mg cap
doxycycline monohydrate pak† (compare to Adoxa Pak®) 1/75 mg, 1/100 mg,
1/150 mg, 2/100 mg
Monodox®* (doxycycline monohydrate) 50 mg, 100 mg cap
Oracea® (doxycycline monohydrate) 40 mg cap
Periostat®* (doxycycline hyclate) 20 mg, 100 mg tab
Vibramycin®* (doxycycline hyclate) 50 mg, 100 mg cap
Vibramycin® (doxycycline hyclate) suspension
Vibratab®* (doxycycline hyclate) 100 mg tab
All other brands

E.E.S.®* (erythromycin ethylsuccinate)
Eryped® (erythromycin ethylsuccinate)
PCE Dispertab® (erythromycin base)
All other brands

Minocin®* (minocycline) 50 mg, 75 mg, 100 mg cap
Dynacin®* (minocycline) 50 mg, 75 mg, 100 mg cap/tab
Solodyn® (minocycline) 45 mg, 90 mg, 135 mg tabs
All other brands

All brands

Accutane®* (isotretinoin) 10 mg, 20 mg, 40 mg caps
All other brands

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy
automatically screened for upon claims processing)

Acne Drugs: Topical Anti-Infectives

Length of Authorization: 1 year

NO PA REQUIRED

BENZOYL PEROXIDE PRODUCTS

BENZOYL PEROXIDE 2.5%, 5%, 10% *G, L, W*; 10% *C*; 3%, 5%, 6%, 8%, 9%, 10% *L*; 3%, 6%, 9% *P* †

CLINDAMYCIN PRODUCTS

CLINDAMYCIN 1% *S, G, L, P* †

ERYTHROMYCIN PRODUCTS

ERYTHROMYCIN 2% *S, G, P* †

SODIUM SULFACETAMIDE PRODUCTS

SODIUM SULFACETAMIDE 10% *L* †

COMBINATION PRODUCTS

ERYTHROMYCIN / BENZOYL PEROXIDE †

SODIUM SULFACETAMIDE / SULFUR *L* †

SODIUM SULFACETAMIDE / SULFUR *W* †

OTHER

PA REQUIRED

Benzac AC® 2.5%, 5%, 10% *G, W*
Benzashave® 5%, 10% *C*
Brevoxyl® 4%, 8% *W*; 4% *G*; 4%, 8% *L*
Clinac BPO® 7% *G*
Desquam-E/X® 2.5%, 5%, 10% *G*; 5%, 10% *W*
Inova 4% *P*
Panoxyl/AQ 2.5%, 5%, 10% *G*; 5%, 10% *B*
Triaz® 3%, 6%, 9% *G*; 3%, 6%, 9% *P*
Zaclir® 4%, 8% *L*
All other brands

Cleocin-T®* (clindamycin 2% *G*)
Evoclin® (clindamycin 2% *F*)
Clindagel® (clindamycin 1% *G*)
All other brands

Akne-Mycin® (erythromycin 2% *O*)
Erygel®* (erythromycin 2% *G*)
All other brands

Klaron®* (sodium sulfacetamide 10% *L*)
All other brands

Benzaclin® (clindamycin/benzoyl peroxide)
DUAC® (clindamycin/benzoyl peroxide) gel, kit
Benzamycin®* (erythromycin/benzoyl peroxide)
Sulfoxyl (erythromycin/benzoyl peroxide)
Z-Clinz® (clindamycin/benzoyl peroxide kit)
All other brands

Avar® (sodium sulfacetamide/sulfur *G*)
Plexion® (sulfacetamide/sulfur *S*)
Rosac®* (sulfacetamide/sulfur *W*)
Rosula®* (sulfacetamide/sulfur *W*)
Sulfacet-R®* (sodium sulfacetamide/sulfur *L*)
Plexion® (sulfacetamide/sulfur *S*)
All other brands

Azelex® (azelaic acid 20% *C*)
All other brands any topical acne anti-infective medication

C=cream, E=emulsion, F=foam, G=gel, L=lotion, O=ointment, P=pads, S=solution, W=wash, B=bar

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Acne Drugs: Topical – Retinoids

Length of Authorization: 1 year

NO PA REQUIRED

TRETINOIN† (specific criteria required for ages <10 or >34) 0.025%, 0.05%, 0.1% C; 0.01%, 0.025% G

TAZORAC® (tazarotene) 0.05%, 0.1% C, G

C=cream, G=gel

PA REQUIRED

All brand tretinoin products (Atralin® 0.05% G, Avita®*, Retin-A®*, Retin-A Micro® 0.1%, 0.04%, Tretin-X® etc.)

Differin® (adapalene) 0.1% C, G; 0.3% G

Avage® (tazarotene) ♣

Renova® (tretinoin) ♣

Solage® (tretinoin/mequinol) ♣

Tri-Luma® (tretinoin/hydroquinone/fluocinolone) ♣

♣ Not indicated for acne. Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles, age spots, etc.).

Acne Drugs: Topical – Rosacea

Length of Authorization: 1 year

NO PA REQUIRED

METRONIDAZOLE† 0.75% C, G, L

C=cream, G=gel, L=lotion

PA REQUIRED

All brand metronidazole products (MetroCream®* 0.75% C, Metrogel®* 0.75% G, Metrogel® 1% G, MetroLotion®* 0.75% L, Noritate® 1% C, Rozex® 0.75% G etc.)

Finacea® (azelaic acid) 15% G

Alzheimer's Medications: Cholinesterase Inhibitors/NMDA Receptor Antagonists

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

CHOLINESTERASE INHIBITORS

ARICEPT® (donepezil) Tablet (QL = 1 tablet/day)

EXELON® (rivastigmine) Capsule (QL = 2 capsules/day)

ARICEPT® ODT (donepezil) (QL = 1 tablet/day)

EXELON® (rivastigmine) Oral Solution

EXELON® (rivastigmine transdermal) Patch (QL = 1 patch/day)

NMDA RECEPTOR ANTAGONIST

NAMENDA® (memantine) Tablet

NAMENDA® (memantine) Oral Solution

PA REQUIRED

Cognex® (tacrine) Capsule §

galantamine† tablet (compare to Razadyne®) Tablet

galantamine ER† capsule (compare to Razadyne ER®)

Razadyne® (galantamine) Tablet §

Razadyne ER® (galantamine) Capsule §

Razadyne® (galantamine) Oral Solution §

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Analgesics: COX-2 Inhibitors

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

CELEBREX[®] (celecoxib) (age ≥ 60 yrs) (QL = 2 capsules/day)

PA REQUIRED

Celebrex[®] (age < 60 yrs) (QL = 2 capsules/day)

Analgesics: Local Anesthetics: Transdermal Patch

Length of Authorization: 6 months

Quantity limits apply

NO PA REQUIRED

PA REQUIRED

Lidoderm[®] Patch (lidocaine 5 %) (QL = 3 patches/day)

Analgesics: Narcotics-Short Acting

Length of Authorization: 3 months, subsequent approval up to 6 months

Acetaminophen Containing Products: Maximum daily dose 4 grams APAP/Day

Quantity limits apply

NO PA REQUIRED

ACETAMINOPHEN W/CODEINE† (compare to Tylenol[®] w/codeine)
ACETAMINOPHEN W/HYDROCODONE† (compare to Vicodin[®],
Lorcet[®], Maxidone[®], Norco[®], Zydone[®])
(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day,
7.5/750 = 5 tablets/day)
ACETAMINOPHEN W/OXYCODONE† (compare to Percocet[®])
(QL 10/650 = 6 tablets/day)
ACETAMINOPHEN W/PROPOXYPHENE† (compare to Darvocet-N[®])
(QL 100/650 = 6 tablets/day)
ASPIRIN W/CODEINE†
ASPIRIN W/OXYCODONE† (compare to Percodan[®])
BUTALBITAL COMP. W/CODEINE† (compare to Fiorinal[®] w/codeine)
CODEINE SULFATE†
DIHYDROCODEINE COMPOUND† (compare to Synalgos-DC[®])
HYDROCODONE† (plain, w/acetaminophen, or w/ibuprofen)
HYDROMORPHONE† (compare to Dilaudid[®])
MEPERIDINE† (compare to Demerol[®]) (30 tabs or 5 day supply)
MORPHINE SULFATE†
MORPHINE SULFATE† (compare to Roxanol[®])
OXYCODONE† (plain, w/acetaminophen or w/ibuprofen)
PENTAZOCINE† (compare to Talwin[®])
PROPOXYPHENE† (compare to Darvon[®])
PROPOXYPHENE COMPOUND.† (compare to Darvon Compound[®])
PROPOXYPHENE N W/ ACETAMINOPHEN†
ROXICET[®] (oxycodone w/ acetaminophen)
ROXICODONE INTENSOL[®] (oxycodone w/ acetaminophen)
ROXICODONE[®] (oxycodone HCL)
TRAMADOL† (compare to Ultram[®])
TRAMADOL/APAP† (compare to Ultracet[®])

PA REQUIRED

Acetaminophen w/ codeine: all branded products
Acetaminophen w/ hydrocodone: all branded products
(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day)
Acetaminophen w/ oxycodone: all branded products
(QL 10/650 = 6 tablets/day)
Actiq[®] (fentanyl lozenge on a stick: 200 mcg, 400 mcg, 600 mcg, 800 mcg,
1200 mcg, 1600 mcg)
Anexsia^{®*}
Bancap HC[®]
Butorphanol Nasal Spray (QL = 2 units/month)
Capital[®] w/Codeine*
Combunox^{®*} (oxycodone w/ibuprofen)
Darvocet-N^{®*} (QL 100/650 = 6 tablets/day)
Darvon Compound^{®*}
Darvon^{®*} / Darvon-N^{®*}
Dazidox^{®*} (oxycodone)
Demerol*
Dilaudid^{®*}
Endocet[®]
Endodan[®]
fentanyl citrate† transmucosal (compare to Actiq[®])
Fentora[®] (fentanyl citrate buccal tablets)
Fioricet w/codeine^{®*}
Ibudone^{®*}
Liquicet^{®*} (hydrocodone w/acetaminophen)
Lorcet^{®*} (also HD, PLUS)
Lortab^{®*}
Magnacet[®]
Maxidone[®]
Meperidine (Qty > 30 tabs or 5 day supply)
Nalbuphine
continued on next page

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

continued from previous page

Norco^{®*}
Nubain^{®*}
Numorphan[®]
Opana[®]
Oxyfast^{®*}
OxyIR^{®*}
Panlor DC[®]
Pentazocine and Naloxone
Percocet^{®*}
Percodan^{®*}
Propoxyphene: all branded products*
Reprexain^{®*}
Roxanol^{®*}
Synalgos DC^{®*}
Talacen^{®*}
Talwin^{®*} and brand combinations/ Talwin NX^{®*}
Trezix[®]
Tylenol[®] #3*
Tylenol[®] #4*
Tylox^{®*}
Ultracet[®]
Ultram^{®*}
Ultram ER[®]
Vicodin^{®*}
Vicoprofen^{®*}
Wygesic^{®*}
Xodol[®]
Zydone^{®*}

Analgesics: Narcotics-Long Acting

Length of Authorization: initial approval 3 months, subsequent approval up to 6 months

Quantity limits apply

Therapy Specific PA fax form for Long Acting Narcotics available on OVHA web-site.

NO PA REQUIRED

TRANSDERMAL

FENTANYL PATCH† (compare to Duragesic[®]) 25 mcg/hr, 50 mcg/hr,
(*QL=15 patches/30 days*)

FENTANYL PATCH† (compare to Duragesic[®]) 75 mcg/hr, 100 mcg/hr,
(*QL=30 patches/30 days*)

ORAL

METHADONE† (compare to Dolophine[®]) 5 mg, 10 mg

MORPHINE SULFATE ER† (compare to MS Contin[®])
(*QL=90 tablets/strength/30 days*)

PA REQUIRED

Duragesic-12[®] 12.5 mcg/hr (*QL=15 patches/30 days*)

Duragesic^{®*} 25 mcg/hr, 50 mcg/hr, (*QL=15 patches/30 days*)

Duragesic^{®*} 75 mcg/hr, 100 mcg/hr (*QL= 30 patches/30 days*)

Fentanyl Patch† (compare to Duragesic[®]) 12.5 mcg/hr (*QL=15 patches/30 days*)

Avinza[®] (morphine sulfate XR) (*QL= 30 capsules/strength/30 days*)

Dolophine^{®*} (methadone)

Kadian[®] (morphine sulfate XR) (*QL= 60 capsules/strength/30 days*)

Methadone 40 mg Dispersible Tablets §

MS Contin^{®*} (morphine sulfate ER) (*QL=90 tablets/strength/30 days*)

Opana ER[®] (oxymorphone ER) (*QL=60 tablets/strength/30 days*)

Oramorph SR^{®*} (morphine sulfate ER) (*QL=90 tablets/strength/30 days*)

Oxycodone ER† (*QL=90 tablets/strength/30 days*)

OxyContin[®] (*QL= 90 tablets/strength/30 days*)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Analgesics: NSAIDs

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

ORAL

DICLOFENAC POTASSIUM† (compare to Cataflam®)
DICLOFENAC SODIUM† (compare to Voltaren®)
DIFLUNISAL† (compare to Dolobid®)
ETODOLAC†
FENOPROFEN† (compare to Nalfon®)
FLURBIPROFEN† (compare to Ansaid®)
IBUPROFEN† (compare to Motrin®)
INDOMETHACIN† (compare to Indocin®)
KETOPROFEN†
KETOPROFEN ER†
MECLOFENAMATE SODIUM† (compare to Meclomen®)
MELOXICAM† tabs (compare to Mobic®)
NABUMETONE†
NAPROXEN† (compare to Naprosyn®)
NAPROXEN SODIUM† (compare to Anaprox®, Naprelan®)
OXAPROZIN† (compare to Daypro®)
PIROXICAM† (compare to Feldene®)
SULINDAC† (compare to Clinoril®)
TOLMETIN SODIUM†

INJECTABLE

KETOROLAC † Injection (QL = 1 dose per fill)

TRANSDERMAL

PA REQUIRED

Anaprox®*
Anaprox DS®*
Ansaid®*
Arthrotec®
Cataflam®*
Clinoril®*
Daypro®*
Dolobid®*
EC-Naprosyn®*
Feldene®*
Indocin®*
Indocin SR®
Ketorolac† QL = 20 doses post PA approval
meloxicam†susp (compare to Mobic®)
Mobic®*
Motrin®*
Nalfon®*

Naprelan®*
Naprosyn®*
Ponstel®
Voltaren®*
Voltaren XR®*

Flector® (diclofenac) Patch
(QL = 2 patches/day)
Voltaren® (diclofenac) Gel

Anemia: Hematopoietic/Erythropoietic Agents

Length of Authorization: 1 year

NO PA REQUIRED

ARANESP® (darbepoetin alfa)
PROCRT® (epoetin alpha)

PA REQUIRED

Epogen® (epoetin alpha)

Ankylosing Spondylitis: Injectables

Length of Authorization: Initial PA 3 months; 12 months thereafter

Therapy-specific PA fax form available on OVHA website.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

ENBREL® (etanercept)
HUMIRA® (adalimumab)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Remicade® (infliximab)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-anxiety: Anxiolytics

Length of Authorization: 1 year

NO PA REQUIRED

Benzodiazepine

ALPRAZOLAM† (compare to Xanax®)
ALPRAZOLAM ER†, ALPRAZOLAM XR® (compare to Xanax XR®)
CHLORDIAZEPOXIDE† (compare to Librium®)
CLONAZEPAM† (compare to Klonopin®)
CLONAZEPAM ODT† (compare to Klonopin Wafers®)
CLORAZEPATE† tabs (compare to Tranxene T®)
DIAZEPAM† (compare to Valium®)
LORAZEPAM† (compare to Ativan®)
OXAZEPAM† (compare to Serax®)

Non-Benzodiazepine

BUSPIRONE† (compare to Buspar®)
HYDROXYZINE HYDROCHLORIDE† (previously Atarax®)
HYDROXYZINE PAMOATE† (compare to Vistaril®)
MEPROBAMATE† (previously Miltown®)

PA REQUIRED

Ativan®* (lorazepam)
Klonopin®* (clonazepam)
Klonopin Wafers®* (clonazepam ODT)
Librium®* (chlordiazepoxide)
Niravam® (alprazolam ODT)
Serax®* (oxazepam)
Tranxene T®* (clorazepate tablets)
Tranxene-SD® (clorazepate SR 24 hr tab)
Valium®* (diazepam)
Xanax®* (alprazolam)
Xanax XR®* (alprazolam XR)

Buspar®* (buspirone)
Vistaril®* (hydroxyzine pamoate)

Anticoagulants

Length of Authorization: 6 months

Quantity limits apply

NO PA REQUIRED

WARFARIN† (compare to Coumadin®)

HEPARIN†

FRAGMIN® (dalteparin)
LOVENOX® (enoxaparin) (QL = 2 syringes/day calculated in ml volume)
ARIXTRA® (fondaparinux)

PA REQUIRED

Coumadin®* (warfarin)

n/a

Innohep® (tinzaparin)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anticonvulsants

Length of Authorization: Lifetime for Seizure Disorders, Duration of Need for Mental Health Indications, 1 Year for Other Indications
Quantity limits apply

NO PA REQUIRED

CARBAMAZEPINE† (compare to Tegretol®)
CARBATROL® (carbamazepine)
CELONTIN® (methsuxamide)
CLONAZEPAM† (compare to Klonopin®)
CLONAZEPAM ODT† (compare to Klonopin Wafers®)
DEPAKOTE® (divalproex sodium)
DEPAKOTE ER® (divalproex sodium)
DIASTAT® (diazepam rectal gel)
DILANTIN® (phenytoin)
EPITOL† (carbamazepine)
ETHOSUXAMIDE† (compare to Zarontin®)
FELBATOL® (felbamate)
GABAPENTIN† (compare to Neurontin®)
GABITRIL® (tiagabine)
KEPPRA® (levetiracetam)
LAMICTAL® tabs (lamotrigine tabs)
LAMICTAL® chew tabs (lamotrigine chew tabs)
NEURONTIN® oral solution (gabapentin)
PEGANONE® (ethotoin)
PHENYTEK® (phenytoin)
PHENYTOIN† (compare to Dilantin®)
PRIMIDONE† (compare to Mysoline®)
TEGRETOL XR® (carbamazepine)
TOPAMAX® (topiramate)
TRILEPTAL® (oxcarbazepine)
VALPROIC ACID† (compare to Depakene®)
ZONISIMIDE† (compare to Zonegran®)

PA REQUIRED

Depakene®* (valproic acid)
divalproex sodium † (compare to Depakote®)
Gabarone®* (gabapentin)
Klonopin®*
Klonopin Wafers®*
lamotrigine† chew tabs (compare to Lamictal® chew tabs)
lamotrigine† tabs (compare to Lamictal® tabs)
levetiracetam† tabs (compare to Keppra® tabs)
Lyrica® (pregabalin) § (*Quantity Limit = 3 capsules/day*)
Mysoline®* (primidone)
Neurontin®* (gabapentin)
oxcarbazepine † (compare to Trileptal®)
Tegretol®* (carbamazepine)
Zarontin®* (ethosuxamide)
Zonegran®* (zonisamide)

Anti-depressants: Miscellaneous

Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications
Quantity limits apply

NO PA REQUIRED

BUDEPRION® SR/BUPROPION SR† (compare to Wellbutrin SR®)
FDA maximum recommended dose = 400 mg/day
BUPROPION† (compare to Wellbutrin®)
FDA maximum recommended dose = 450 mg/day
MAPROTILINE† (previously Ludiomil®)
FDA maximum recommended dose = 225 mg/day
MIRTAZAPINE† (compare to Remeron®)
FDA maximum recommended dose = 45 mg/day
MIRTAZAPINE RDT† (compare to Remeron Sol-Tab®)
FDA maximum recommended dose = 45 mg/day
NEFAZADONE† (previously Serzone®)
FDA maximum recommended dose = 600 mg/day
TRAZODONE HCL† (previously Desyrel®)
FDA maximum recommended dose = 600 mg/day
WELLBUTRIN XL® (bupropion XL)
FDA maximum recommended dose = 450 mg/day

PA REQUIRED

Budeprion XR/bupropion XL† (compare to Wellbutrin XL®)
FDA maximum recommended dose = 450 mg/day
Remeron®* (mirtazapine)
FDA maximum recommended dose = 45 mg/day
Remeron Sol Tab®* (mirtazapine RDT)
FDA maximum recommended dose = 45 mg/day
Wellbutrin®* (bupropion)
FDA maximum recommended dose = 450 mg/day
Wellbutrin SR®* (bupropion SR)
FDA maximum recommended dose = 400mg/day

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-depressants: SNRIs

Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications

Quantity limits apply

NO PA REQUIRED

PA REQUIRED

Cymbalta[®] § (duloxetine)
FDA maximum recommended dose = 60 mg/day
Effexor[®] (venlafaxine IR)
FDA maximum recommended dose = 225 mg/day
Effexor XR[®] § (venlafaxine XR)
FDA maximum recommended dose = 225 mg/day,
Quantity limit = 1 capsule/day (37.5 mg & 75 mg)
Pristiq[®] § (desvenlafaxine)
FDA maximum recommended dose = 400 mg/day,
Quantity limit = 1 tablet/day (50 mg tablet only)
venlafaxine IR †§ (compare to Effexor[®])
FDA maximum recommended dose = 225 mg/day
Venlafaxine ER[®] § tablet
FDA maximum recommended dose = 225 mg/day,
Quantity limit = 1 tablet/day (37.5 mg & 75 mg)

Anti-depressants: SSRIs

Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications

Quantity limits apply

NO PA REQUIRED

PA REQUIRED

CITALOPRAM† (compare to Celexa[®])
FDA maximum recommended dose = 40 mg/day
FLUOXETINE† (compare to Prozac[®])
FDA maximum recommended dose = 80 mg/day
FLUVOXAMINE† (previously Luvox[®])
FDA maximum recommended dose = 300 mg/day
PAROXETINE tablet† (compare to Paxil[®])
FDA maximum recommended dose = 60 mg/day
SERTRALINE† (compare to Zoloft[®])
FDA maximum recommended dose = 200 mg/day,
Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)

Celexa^{®*} (citalopram)
FDA maximum recommended dose = 40 mg/day
Lexapro[®] (escitalopram)
FDA maximum recommended dose = 20 mg/day,
Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)
Luvox CR[®] (fluvoxamine CR)
FDA maximum recommended dose = 300 mg/day,
Quantity limit = 2 capsules/day
paroxetine suspension† (compare to Paxil[®] susp)
FDA maximum recommended dose = 60 mg/day
Paroxetine CR† (compare to Paxil CR[®])
FDA maximum recommended dose = 75 mg/day
Paxil^{®*} (paroxetine)
FDA maximum recommended dose = 60 mg/day
Paxil CR[®] (paroxetine CR)
FDA maximum recommended dose = 75 mg/day
Pexeva[®] (paroxetine)
FDA maximum recommended dose = 60 mg/day
Prozac^{®*} (fluoxetine)
FDA maximum recommended dose = 80 mg/day
Prozac Weekly[®] (fluoxetine)
FDA maximum recommended dose = 90 mg/week
Sarafem[®] (fluoxetine)
FDA maximum recommended dose = 80 mg/day
Selfemra[®] (fluoxetine)
FDA maximum recommended dose = 80 mg/day
Zoloft^{®*} (sertraline)
FDA maximum recommended dose = 200 mg/day,
Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-depressants: Tricyclics

Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications

NO PA REQUIRED

AMITRIPTYLINE† (previously Elavil®)
FDA maximum recommended dose = 300 mg/day
AMITRIPTYLINE/CHLORDIAZ.† (compare to Limbitrol®, Limbitrol DS®)
AMITRIPTYLINE/PERPHEN† (previously Etrafon®, Triavil®)
AMOXAPINE† (previously Asendin®)
CLOMIPRAMINE† (compare to Anafranil®)
DESIPRAMINE† (compare to Norpramin®)
DOXEPIN† (previously Sinequan®)
IMIPRAMINE† (compare to Tofranil®)
FDA maximum recommended dose = 300 mg/day
IMIPRAMINE PAMOATE† (compare to Tofranil PM®)
NORTRIPTYLINE† (previously Aventyl®, compare to Pamelor®)
PROTRIPTYLINE† (compare to Vivactil®)
TRIMIPRAMINE (compare to Surmontil®)

PA REQUIRED

Anafranil®* (clomipramine)
Limbitrol®* (amitriptyline/chlordiazepoxide)
Limbitrol DS®* (amitriptyline/chlordiazepoxide)
Norpramin®* (desipramine)
Pamelor®* (nortriptyline)
Surmontil®* (trimipramine)
Tofranil®* (imipramine)
FDA maximum recommended dose = 300 mg/day
Tofranil PM®* (imipramine pamoate)
Vivactil®* (protriptyline)

Anti-depressants: MAO Inhibitors

Length of Authorization: Duration of Need for Mental Health Indications

Quantity limits apply

NO PA REQUIRED

NARDIL® (phenylzine)
FDA maximum recommended dose = 90 mg/day
TRANLYCYPROMINE (compare to Parnate®)
FDA maximum recommended dose = 60 mg/day

PA REQUIRED

EMSAM® (selegiline) (*QL = 1 patch/day*)
Marplan® (isocarboxazid)
Parnate®* (tranlycypromine)
FDA maximum recommended dose = 60 mg/day

Anti-diabetics: Alpha-Glucosidase Inhibitors

Length of Authorization: 1 year

NO PA REQUIRED

ACARBOSE† (compare to Precose®)
GLYSET® (miglitol)

PA REQUIRED

PRECOSE®* (acarbose)

Anti-diabetic: Biguanides & Combinations

Length of Authorization: 1 year

NO PA REQUIRED

GLIPIZIDE/METFORMIN† (compare to Metaglip®)
GLYBURIDE/METFORMIN† (compare to Glucovance®)
METFORMIN† (compare to Glucophage®)
METFORMIN XR† (compare to Glucophage XR®)
RIOMET® (metformin oral solution)

PA REQUIRED

Fortamet®
Glucophage®*
Glucophage XR®*
Glucovance®*
Glumetza®
Metaglip®*

Anti-diabetics: Peptide Hormones

Length of Authorization: 1 year

Quantity limits apply

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Byetta® (exenatide) § (*Quantity Limit = 1 pen/30 days*)

PA REQUIRED

Symmlin® (pramlintide) *No Quantity Limit*

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-diabetics: Insulins
Length of Authorization: lifetime

NO PA REQUIRED

RAPID-ACTING INJECTABLE

NOVOLOG[®] (Aspart)

SHORT-ACTING INJECTABLE

NOVOLIN R[®] (Regular)

INTERMEDIATE-ACTING INJECTABLE

NOVOLIN N[®] (NPH)

LONG-ACTING ANALOGS INJECTABLE

LANTUS[®] (insulin glargine)
 LEVEMIR[®] (insulin detemir)

MIXED INSULINS INJECTABLE

HUMULIN 50/50[®] (NPH/Regular)
 NOVOLIN 70/30[®] (NPH/Regular)

NOVOLOG MIX 70/30[®] (Protamine/Aspart)

HUMALOG MIX 50/50[®] (Protamine/Lispro)
 HUMALOG MIX 75/25[®] (Protamine/Lispro)

PA REQUIRED

Apidra[®] (insulin glulisine)
 Humalog[®] (insulin lispro)

Humulin R[®] (Regular)
 ReliOn R[®] (Regular)

Humulin N[®] (NPH)
 ReliOn N[®] (NPH)

Humulin 70/30[®] (NPH/Regular)
 ReliOn 70/30[®] (NPH/Regular)

Anti-diabetic: Oral Meglitinides
Length of Authorization: 1 year

NO PA REQUIRED

STARLIX[®] (nateglinide)

PA REQUIRED

Prandin[®] (replaglinide)

Anti-diabetic: Sulfonylureas 2nd Generation
Length of Authorization: 1 year

NO PA REQUIRED

GLIMEPIRIDE[†] (compare to Amaryl[®])
 GLIPIZIDE[†] (compare to Glucotrol[®])
 GLIPIZIDE ER[†] (compare to Glucotrol XL[®])
 GLYBURIDE[†] (compare to Diabeta[®], Micronase[®])
 GLYBURIDE MICRONIZED[†] (compare to Glynase[®] PresTab[®])

PA REQUIRED

Amaryl^{®*}
 Diabeta^{®*}
 Glucotrol^{®*}
 Glucotrol XL^{®*}
 Glynase[®] PresTab^{®*}
 Micronase^{®*}

PDL Key:

[†] Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-diabetic: Thiazolidinediones & Combinations

Length of Authorization: 1 year

Quantity limits apply

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

SINGLE AGENT

ACTOS® (pioglitazone) §

AVANDIA® (rosiglitazone) §

COMBINATION

ACTOPLUS MET® (metformin/pioglitazone) §

AVANDAMET® (metformin/rosiglitazone maleate) §

AVANDARYL® (glimepiride/rosiglitazone maleate) §

DUETACT® (pioglitazone/glimepiride) § (*Quantity Limit = 1 tablet/day*)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Anti-diabetic: Dipeptidyl Peptidase (DPP-4) Inhibitors

Length of Authorization: 1 year

Quantity limits apply

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

JANUVIA® (sitagliptin) § (*Quantity Limit = 1 tablet/day*)

JANUMET® (sitagliptin/metformin) § (*Quantity Limit = 2 tablets/day*)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Anti-emetics: NK1/5HT3 Antagonists

Length of Authorization: 6 months for chemotherapy or radiotherapy;

1 time for prevention of post-op nausea/vomiting: see clinical criteria.

Monthly quantity limits apply, PA required to exceed.

NO PA REQUIRED

EMEND® (aprepitant) 40 mg (1 cap/30 days)

*EMEND® (aprepitant) 80 mg (2 caps/30 days)

*EMEND® (aprepitant) 125 mg (1 cap/30 days)

*EMEND® (aprepitant) Tri-fold Pack (1 pack/30 days)

ONDANSETRON† Injection (vial and premix)

ONDANSETRON† tablet 4 mg (12 tabs/month), 8 mg (6 tabs/month)

ONDANSETRON† ODT 4 mg (12 tabs/month), 8 mg (6 tabs/month)

* *To be prescribed by oncology practitioners ONLY*

PA REQUIRED

Aloxi® (palonosetron, injectable) (2 vials/month)

Anzemet® (dolansetron) 50 mg (4 tabs/month)

Anzemet® (dolansetron) 100 mg (2 tabs/month)

*Emend® (fosaprepitant) 115 mg Injection (Qty Limit = 1 vial/30 days)

Granisetron† (compare to Kytril®) 1 mg (6 tabs/month)

Granisetron† (compare to Kytril®) Injectable

Granisetron† (compare to Kytril®) Oral Solution

Kytril® (granisetron) 1 mg (6 tabs/month)

Kytril® (granisetron) Injectable

Ondansetron† (generic) 24 mg (1 tab/month)

Ondansetron† (generic) Oral Solution 4 mg/5 ml

Zofran®* (ondansetron) Injection

Zofran®* (ondansetron) Oral Tablets and ODT 4 mg (12 tabs/month),

8 mg (6 tabs/month)

Zofran® (ondansetron) Oral Solution 4 mg/5 ml

Anti-emetics: Other

Length of Authorization: Initial approval 3 months, subsequent approval up to 6 months

Quantity limits apply

NO PA REQUIRED

PA REQUIRED

Dronabinol† (compare to Marinol®) (*Quantity Limit = 30 days supply for AIDS anorexia or quantity required for one chemotherapy treatment course*)

Marinol® (dronabinol) (*Quantity Limit = 30 days supply for AIDS anorexia or quantity required for one chemotherapy treatment course*)

Cesamet® (nabilone) (*Quantity Limit = quantity required for one chemotherapy treatment course*)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Antihyperkinesia: ADHD, ADD, Narcolepsy

Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications
CNS Stimulants (all forms short- & long-acting): PA'd for beneficiaries < 3 yrs
Quantity limits apply

NO PA REQUIRED

SHORT/INTERMEDIATE ACTING METHYLPHENIDATE PREPS

METADATE ER[®] (compare to Ritalin[®] SR)
METHYLIN[®] (compare to Ritalin[®])
METHYLIN[®] ER (compare to Ritalin[®] SR)
METHYLPHENIDATE † (compare to Ritalin[®])
METHYLPHENIDATE SR † (compare to Ritalin[®] SR)

PA REQUIRED

Dexmethylphenidate † (compare to Focalin[®])
Focalin[®] (dexmethylphenidate)
Ritalin[®]* (methylphenidate)
Ritalin SR[®]* (methylphenidate SR)

LONG-ACTING METHYLPHENIDATE PREPS

Oral

CONCERTA[®] (methylphenidate IR/ER 22:78%)
FOCALIN[®] XR (dexmethylphenidate IR/ER, 50:50%)

Metadate CD[®] (methylphenidate, IR/ER, 30:70%)
Ritalin LA[®] (methylphenidate, IR/ER, 50:50%)

Transdermal

DAYTRANA[®] (methylphenidate patch) (QL = 1 patch/day)

SHORT/INTERMEDIATE AMPHETAMINE PREPS

AMPHETAMINE salt combo† (compare to Adderall[®])
DEXTROAMPHETAMINE † (previously Dexedrine[®])
DEXTROAMPHETAMINE SR† (compare to Dexedrine CR[®])
DEXTROSTAT † (dextroamphetamine)

Adderall[®]* (amphetamine salt combo)
Desoxyn[®] (methamphetamine)
Dexedrine CR[®]* (dextroamphetamine SR)

LONG-ACTING AMPHETAMINE PREPS

ADDERALL XR[®] (dextroamphetamine IR/ER, 50:50%)
VYVANSE[®] (lisdexamfetamine) (QL = 1 capsule/day)

NON-STIMULANT PREPS

Provigil[®] (modafinil) (not approvable for ADHD in children age ≤12).

Strattera[®] (atomoxetine)
FDA maximum recommended dose = 100 mg/day

Xyrem[®] (sodium oxybate)

Anti-hypertensives: ACE Inhibitors

Length of Authorization: 1 year

NO PA REQUIRED

BENAZEPRIL† (compare to Lotensin[®])
CAPTOPRIL† (compare to Capoten[®])
ENALAPRIL† (compare to Vasotec[®])
FOSINOPRIL† (compare to Monopril[®])
LISINOPRIL† (compare to Zestril[®], Prinivil[®])
MOEXIPRIL† (compare to Univasce[®])
QUINAPRIL† (compare to Accupril[®])

PA REQUIRED

Accupril[®]*
Aceon[®] (perindopril)
Altace[®] (ramipril)
Capoten[®]*
Lotensin[®]*
Mavik[®] (trandolapril)
Monopril[®]*
Prinivil[®]*
ramipril† (compare to Altace[®])
trandolapril† (compare to Mavik[®])
Univasce[®]* (moexipril)
Vasotec[®]*
Zestril[®]*

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-hypertensives: ACE Inhibitor with Hydrochlorothiazide

Length of Authorization: 1 year

NO PA REQUIRED

BENAZEPRIL/HYDROCHLOROTHIAZIDE† (compare to Lotensin HCT®)
CAPTOPRIL/HYDROCHLOROTHIAZIDE† (compare to Capozide®)
ENALAPRIL/HYDROCHLOROTHIAZIDE† (compare to Vasoretic®)
FOSINOPRIL/HYDROCHLOROTHIAZIDE† (compare to Monopril HCT®)
LISINOPRIL/HYDROCHLOROTHIAZIDE† (compare to Zestoretic®, Prinzide®)
QUINAPRIL/HYDROCHLOROTHIAZIDE† (compare to Accuretic®)

PA REQUIRED

Accuretic®*
Capozide®*
Lotensin HCT®*
moexipril/hydrochlorothiazide† (compare to Uniretic®)
Monopril HCT®*
Prinzide®*
Uniretic® (moexipril/hydrochlorothiazide)
Vasoretic®*
Zestoretic®*

Anti-hypertensives: ACE Inhibitor w/Calcium Channel Blocker

Length of Authorization: 1 year

NO PA REQUIRED

BENAZEPRIL/AMLODIPINE † (compare to Lotrel®)

PA REQUIRED

Lexxel® (enalapril/felodipine)
Lotrel® (benazepril/amlodipine)
Tarka® (trandolopril/verapamil)

Anti-hypertensives: Angiotensin Receptor Blockers (ARBs)

Length of Authorization: lifetime

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

AVAPRO® (irbesartan) §
BENICAR® (olmesartan) §
COZAAR® (losartan) §
DIOVAN® (valsartan) §
MICARDIS® (telmisartan) §

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Atacand® (candesartan) §
Teveten® (eprosartan) §

Anti-hypertensives: Angiotensin Receptor Blocker/Hydrochlorothiazide Combinations

Length of Authorization: lifetime

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

AVALIDE® (irbesartan/hydrochlorothiazide) §
BENICAR HCT® (olmesartan/hydrochlorothiazide) §
DIOVAN HCT® (valsartan/hydrochlorothiazide) §
HYZAAR® (losartan/hydrochlorothiazide) §
MICARDIS HCT® (telmisartan/hydrochlorothiazide) §

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Atacand HCT® (candesartan/hydrochlorothiazide) §
Teveten HCT® (eprosartan/hydrochlorothiazide) §

Anti-hypertensives: Angiotensin Receptor Blocker/Calcium Channel Blocker Combinations

Length of Authorization: lifetime

Quantity limits apply

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

EXFORGE® (valsartan/amlodipine) § (*Quantity Limit = 1 tablet/day*)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Azor® (olmesartan/amlodipine) (*Quantity Limit = 1 tablet/day*)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-hypertensives: Beta Blockers

Length of Authorization: 5 years

NO PA REQUIRED

SINGLE AGENT

ACEBUTOLOL† (compare to Sectral®)
ATENOLOL† (compare to Tenormin®)
BETAXOLOL† (compare to Kerlone®)
BISOPROLOL FUMARATE† (compare to Zebeta®)
CARVEDILOL† (compare to Coreg®)
LABETALOL† (compare to Normodyne®, Trandate®)
METOPROLOL† (compare to Lopressor®)
METOPROLOL XL† (compare to Toprol XL®)
NADOLOL† (compare to Corgard®)
PINDOLOL† (compare to Viskin®)
PROPRANOLOL† (compare to Inderal®)
SOTALOL† (compare to Betapace®, Betapace AF®)
TIMOLOL† (compare to Blocadren®)

BETA-BLOCKER/DIURETIC COMBINATION

ATENOLOL/CHLORTHALIDONE † (compare to Tenoretic®)
BISOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Ziac®)
METOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Lopressor HCT®)
PROPRANOLOL/HYDROCHLOROTHIAZIDE† (compare to Inderide®)

PA REQUIRED

Betapace®*	Kerlone®*
Betapace AF®*	LevatoL® (penbutolol)
Blocadren®*	Lopressor®* (all products)
Bystolic® (nebivolol) (QL = 1 tablet/day for 2.5 mg and 5 mg tablet strengths)	propranolol ER† (compare to Inderal LA®)
Cartrol®	Sectral®*
Coreg®	Tenormin®*
Coreg CR®	Toprol XL®* (metoprolol succinate)
Corgard®	Trandate®*
Inderal®* (all products)	Zebeta®*
Inderal LA®	
Innopran XL®	
Corzide®	Tenoretic®*
Inderide®*	Timolide®
Lopressor HCT®*	(timolol/hydrochlorothiazide)
Nadolol/bendroflumethiazide† (compare to Corzide®)	Ziac®*

Anti-hypertensives: Calcium Channel Blockers

Length of Authorization: 5 years

Quantity limits apply

NO PA REQUIRED

AMLODIPINE† (compare to Norvasc®)
CARTIA XT® (diltiazem HCL)
DILTIA XT® (diltiazem HCL)
DILTIAZEM† (compare to Cardizem®)
DILTIAZEM ER† (compare to Cardizem® SR)
DILTIAZEM CD† (compare to Cardizem® CD)
DILTIAZEM XR† (compare to Dilacor® XR)
FELODIPINE† (compare to Plendil®)
NICARDIPINE† (compare to Cardene®)
NIFEDIAZEM CC (compare to Adalat CC®)
NIFEDICAL XL† (compare to Procardia® XL)
NIFEDIPINE IR† (compare to Procardia®)
NIFEDIPINE ER† (compare to Procardia® XL)
NIMODIPINE† (compare to Nimotop®)
TAZTIA XT® (compare to Tiazac®)
VERAPAMIL† (compare to Calan®)
VERAPAMIL CR† (compare to Calan SR®, Isoptin SR®)
VERAPAMIL SR† 120 mg, 180 mg 240 mg and 360 mg (compare to Verelan®)

EXFORGE® (valsartan/amlodipine) § (Quantity Limit = 1 tablet/day)

PA REQUIRED

Adalat® CC*
Calan®*
Calan® SR*
Cardene®*
Cardene® SR (no AB rated generic)
Cardizem®*, Cardizem® CD*
Cardizem® LA (no AB rated generic)
Covera-HS® (no AB rated generic)
Dilacor® XR*
Dynacirc CR® (no AB rated generic)
Isoptin® SR*
isradipine†
Nimotop®* (nimodipine)
Norvasc®* (amlodipine)
Plendil®*
Procardia®*
Procardia® XL*
Sular® (nisoldipine)
Tiazac®*
verapamil SR †100 mg, 200 mg, 300mg (compare to Verelan PM®)
Verelan®*
Verelan PM®

Azor® (olmesartan/amlodipine) (Quantity Limit = 1 tablet/day)
Caduet® (amlodipine/atorvastatin)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-hypertensives: Renin Inhibitor

Length of Authorization: lifetime

Quantity limits apply

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

SINGLE AGENT

TEKTURNA[®] (aliskiren) § (*Quantity Limit = 1 tablet/day*)

COMBINATION

TEKTURNA HCT[®] (aliskiren/hydrochlorothiazide) § (*Quantity Limit = 1 tablet/day*)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Anti-infectives: Cephalosporins – 1st Generation

Length of Authorization: for date of service, no refills

NO PA REQUIRED

CEFADROXIL† (compare to Duricef[®])

CEPHALEXIN† (compare to Keflex[®])

IV drugs are not managed at this time

PA REQUIRED

Duricef[®]*

Keflex[®]*

Anti-infectives: Cephalosporins – 2nd Generation

Length of Authorization: for date of service, only: no refills

NO PA REQUIRED

TABLETS

CEFACLOR CAPSULE†

CEFACLOR ER TABLET†

CEFPROZIL TABLET† (compare to Cefzil[®])

CEFUROXIME TABLET† (compare to Cefitin[®])

SUSPENSION

CEFACLOR SUSPENSION†

CEFPROZIL SUSPENSION† (compare to Cefzil[®])

CEFTIN[®] (cefuroxime) SUSPENSION

IV drugs are not managed at this time

PA REQUIRED

Cefitin[®]* tablet

Cefzil[®] tablet

Lorabid[®] (loracarbef) capsule

Cefuroxime† Suspension (compare to Cefitin[®])

Cefzil[®] suspension

Lorabid[®] (loracarbef) suspension

Anti-infectives: Cephalosporins – 3rd Generation

Length of Authorization: for date of service, no refills

NO PA REQUIRED

CAPSULES/TABLETS

CEFPODOXIME PROXETIL TABS† (compare to Vantin[®])

OMNICEF[®] CAPSULE (cefdinir)

SUSPENSION

OMNICEF[®] SUSPENSION(cefdinir)

SUPRAX[®] SUSPENSION (cefixime)

IV drugs are not managed at this time

PA REQUIRED

Cedax[®] capsule (ceftibuten)

cefdinir capsule†

Spectracef[®] tablet (cefditoren)

Vantin[®]* tablet (cefpodoxime)

Cedax[®] suspension (ceftibuten)

cefdinir suspension †

cefpodoxime proxetil† (compare to Vantin[®]) suspension

Vantin[®] suspension (cefpodoxime)

Anti-infectives: Ketolides

Length of Authorization: for date of service, no refills

NO PA REQUIRED

PA REQUIRED

Ketek[®] (telithromycin)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-infectives: Macrolides

Length of Authorization: for date of service, no refills

NO PA REQUIRED

AZITHROMYCIN† tablets (≤5 day supply) (compare to Zithromax®)
AZITHROMYCIN† liquid (≤ 5 day supply) (compare to Zithromax®)

CLARITHROMYCIN† (compare to Biaxin/Biaxin XL)

ERY-TAB® (erythromycin base, delayed release)
ERYTHROCIN† (erythromycin stearate)
ERYTHROMYCIN BASE†
ERYTHROMYCIN ESTOLATE†
ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S.®, Eryped®)
ERYTHROMYCIN STEARATE†
ERYTHROMYCIN W/ SULFASOXAZOLE† (compare to Pediazole®)
IV drugs are not managed at this time

PA REQUIRED

azithromycin† tablets and liquid (if > 5 day supply)
Biaxin®*
Biaxin XL®
Dynabac® (dirithromycin)
E.E.S.®*
Eryped® (erythromycin ethylsuccinate)
PCE Dispertab® (erythromycin base)
Pediazole®* (erythromycin-sulfisoxazole)
Zithromax® tablets and liquid
Zmax® (azithromycin extended release oral suspension)

Anti-infectives: Oxazolidinones

Length of Authorization: 28 days, no refills

Quantity Limits Apply

NO PA REQUIRED

IV form of this medication not managed at this time

PA REQUIRED

Zyvox® (linezolid) (QL = 56 tablets per 28 days)

Anti-infectives: Penicillins (Oral)

Length of Authorization: for date of service, no refills

NO PA REQUIRED

AMOXICILLIN† (compare to Amoxil®, Trimox®, DisperMox™)
AMOXICILLIN/CLAVULANATE† (compare to Augmentin®)
AMPICILLIN† (compare to Principen®)
DICLOXACILLIN†
PENICILLIN VK† (compare to Veetids®)

PA REQUIRED

Augmentin®**
Augmentin ES®**
Augmentin XR®

* PA will be granted for 125 mg/5 mL strength for patients < 12 weeks of age

Anti-infectives: Quinolones

Length of Authorization: for date of service, no refills

NO PA REQUIRED

CIPROFLOXACIN† (compare to Cipro®)
CIPRO® OS (ciprofloxacin oral solution) 100 mg/ml
LEVAQUIN® (levofloxacin)
OFLOXACIN†

IV drugs are not managed at this time

PA REQUIRED

Avelox® (moxifloxacin HCL)
Avelox ABC PACK® (moxifloxacin HCL)
Cipro®*
Cipro XR®
ciprofloxacin ER†
Factive® (gemifloxacin)
Noroxin® (norfloxacin)
ProQuin XR® (ciprofloxacin)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-infectives: Influenza Vaccines

Length of Authorization: for date of service only

Note: Influenza Nasal Vaccine provided free of charge and without PA by Vermont Department of Health for ages 2 – 18 years

NO PA REQUIRED

AFLURIA[®] Injection
FLUARIX[®] Injection
FLUZONE[®] Injection
FLUVIRIN[®] Injection

PA REQUIRED

FluMist[®] Nasal

Anti-infectives: Miscellaneous

Length of Authorization: 1 year

NO PA REQUIRED

PA REQUIRED

Quaalun[®] (quinine sulfate)

Anti-infectives: Topical Antibiotics

Length of Authorization: for date of service, no refills

Quantity limits apply

NO PA REQUIRED

BACITRACIN[†]
GENTAMICIN[†]
BACITRACIN-POLYMXIN[†]
NEOMYCIN-BACITRACIN-POLYMXIN[†]
CORTISPORIN[®]
BACTROBAN[®] OINTMENT
MUPIROCIN OINTMENT (compare to Bactroban[®])

PA REQUIRED

Altabax[®] (retapamulin) (*Quantity Limit = 1 tube*)
Bactroban[®] CREAM

Anti-migraine: Triptans

Length of Authorization: 6 months

Monthly quantity limits apply, PA required to exceed.

NO PA REQUIRED, Quantity Limits Apply

Single Agent

ORAL

AXERT[®] (almotriptan) 6.25 mg, 12.5 mg

Quantity Limit = 6 tablets/month

IMITREX[®] (sumatriptan)

Quantity Limit = 18 tablets/month (25 mg),

9 tablets/month (50 mg, 100 mg),

MAXALT[®] (rizatriptan) tablet or MAXALT-MLT[®] (rizatriptan ODT)

5 mg, 10 mg

Quantity Limit = 12 tablets/month

NASAL SPRAY

IMITREX[®] (sumatriptan)

Quantity Limit = 12 units/month (5 mg nasal spray),

6 units/month (20 mg nasal spray)

INJECTABLE

IMITREX[®] (sumatriptan)

Quantity Limit = 4 injections/month (4 or 6 mg injection)

Combination Product (Oral)

PA REQUIRED, Quantity Limits Apply

Amerge[®] (naratriptan) 1 mg, 2.5 mg

Quantity Limit = 9 tablets/month

Frova[®] (frovatriptan) 2.5 mg

Quantity Limit = 9 tablets/month

Relpax[®] (eletriptan) 20 mg, 40 mg

Quantity Limit = 12 tablets/month

Zomig[®] (zolmitriptan)

Quantity Limit = 12 tablets/month (2.5 mg tablets or orally disintegrating tablets), 6 tablets/month (5 mg tablets or orally disintegrating tablets)

Zomig[®] (zolmitriptan)

Quantity Limit = 12 units/month (5 mg nasal spray)

sumatriptan (compare to Imitrex[®])

Quantity Limit = 4 injections/month (4 or 6 mg injection)

Treximet[®] (sumatriptan/naproxen)

Quantity Limit = 9 tablets/month

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-obesity

*Length of Authorization: 6 months for initial approval,
may renew for additional 6 months if patient has met target goals.
Quantity limits apply*

Therapy specific PA fax form available on OVHA website.

NO PA REQUIRED

PA REQUIRED

Alli[®] (orlistat OTC) *QL = 3 capsules/day*
benzphetamine† (all forms brand & generic)
diethylpropion† (all forms brand & generic)
Meridia[®] (sibutramine)
phentermine† (all forms brand & generic)
phendimetrazine† (all forms brand & generic)
Xenical[®] (orlistat)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-psychotic: Atypical & Combinations

Length of Authorization: Duration of Need

Quantity limits apply

NO PA REQUIRED

TABLETS/CAPSULES

CLOZAPINE† (compare to Clozaril®)

FDA maximum recommended dose = 900 mg/day

GEODON® (ziprasidone)

FDA maximum recommended dose = 160 mg/day

RISPERDAL® (risperidone)

FDA maximum recommended dose = 16 mg/day

SEROQUEL® (quetiapine)

FDA maximum recommended dose = 800 mg/day

ORAL SOLUTIONS

RISPERDAL® (risperidone) oral solution

FDA maximum recommended dose = 16 mg/day

SHORT-ACTING INJECTABLE PRODUCTS

GEODON® IM (ziprasidone intramuscular injection)

FDA maximum recommended dose = 40 mg/day

LONG-ACTING INJECTABLE PRODUCTS

ORALLY DISINTEGRATING TABLETS

COMBINATION PRODUCTS

PA REQUIRED

Abilify® (aripiprazole)

FDA maximum recommended dose = 30 mg/day,

Quantity limit = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)

Clozaril®* (clozapine)

FDA maximum recommended dose = 900 mg/day

Invega® (paliperidone)

FDA maximum recommended dose = 12 mg/day

Quantity limit = 1 tab/day (3mg, 9mg), 2 tabs/day (6mg)

Risperidone† (compare to Risperdal®)

FDA maximum recommended dose = 16 mg/day

Seroquel XR® (quetiapine XR)

FDA maximum recommended dose = 800 mg/day

Quantity Limit = 1 tab/day (200 mg tablet strength only)

Zyprexa® (olanzapine)

FDA maximum recommended dose = 20 mg/day,

Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)

Abilify® (aripiprazole) oral solution

FDA maximum recommended dose = 25 mg/day

Abilify® IM (aripiprazole intramuscular injection)

FDA maximum recommended dose = 30 mg/day

Zyprexa® IM (olanzapine intramuscular injection)

FDA maximum recommended dose = 30 mg/day

Risperdal® Consta (risperidone microspheres)

FDA maximum recommended dose = 50 mg/14 days

Abilify® Discmelt (aripiprazole)

FDA maximum recommended dose = 30 mg/day,

Quantity limit = 1.5 tabs/day (10 mg & 15 mg tabs)

FazaClo® (clozapine orally disintegrating tablets)

FDA maximum recommended dose = 900 mg/day

Risperdal® M-Tab (risperidone orally disintegrating tablets)

FDA maximum recommended dose = 16 mg/day

Zyprexa Zydis® (olanzapine orally disintegrating tablets)

FDA maximum recommended dose = 20 mg/day,

Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)

Symbyax® (olanzapine/fluoxetine)

FDA maximum recommended dose = 18 mg/75 mg (perday)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Anti-psychotic: Typicals

Length of Authorization: Duration of Need for Mental Health Indications

NO PA REQUIRED

CHLORPROMAZINE† (compare to Thorazine®)
FLUPHENAZINE† (compare to Prolixin®, Prolixin®)
HALOPERIDOL† (compare to Haldol®)
LOXAPINE† (compare to Loxitane®)
MOBAN® (molindone)
PERPHENAZINE† (compare to Trilafon®)
THIORIDAZINE† (compare to Mellaril®)
THIOTHIXENE† (compare to Navane®)
TRIFLUOPERAZINE† (compare to Stelazine®)

PA REQUIRED

Haldol®*
Loxitane®*
Mellaril®*
Navane®*
Prolixin®*
Thorazine®*
Trilafon®*

Botulinum toxins

Length of Authorization: Initial Approval 3 months, Subsequent approval up to 12 months

NO PA REQUIRED

PA REQUIRED

Botox®
Botox® Cosmetic
Myobloc®

BPH: Alpha Blockers

Length of Authorization: 1 year

NO PA REQUIRED

DOXAZOSIN† (compare to Cardura®)
FLOMAX® (tamsulosin)
TERAZOSIN† (compare to Hytrin®)
UROXATRAL® (alfuzosin)

PA REQUIRED

Cardura®*, Cardura XL®
Hytrin®*

BPH: Androgen Hormone Inhibitors

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

AVODART® (dutasteride) (*QL = 1 capsule/day*)
FINASTERIDE† (compare to Proscar®) (*QL = 1 tablet/day*)
PROSCAR® (finasteride) (*QL = 1 tablet/day*)

PA REQUIRED

Avodart® (dutasteride) females; males age < 45 (*QL = 1 capsule/day*)
finasteride† (compare to Proscar®) females; males age < 45 (*QL = 1 tablet/day*)
Proscar® (finasteride) females; males age < 45 (*QL = 1 tablet/day*)

Cardiac Glycosides

Length of Authorization: n/a

NO PA REQUIRED

DIGITEK® (digoxin)
DIGOXIN†
LANOXICAPS® (digoxin)
LANOXIN® (digoxin)

PA REQUIRED

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Chemical Dependency: Alcohol and Opiate Dependency

*Length of Authorization: Vivitrol – 6 months, no renewal, All Others 1 year
 DATA 2000 Waiver (“X” number) required for prescribers of Buprenorphine
 Quantity limits apply*

Vivitrol and Buprenorphine Therapy specific PA fax forms are available on OVHA website.

NO PA REQUIRED**Alcohol Dependency**

ANTABUSE® (disulfiram)
 CAMPRAL® (acamprosate)
 NALTREXONE oral † (compare to Revia®)

Opiate Dependency

NALTREXONE oral † (compare to Revia®)

Note: Methadone for opiate dependency can only be prescribed through a Methadone Maintenance Clinic

PA REQUIRED

Revia®* (naltrexone oral)

Vivitrol® (naltrexone for extended-release injectable suspension) (*QL = 1 injection (380 mg) per 30 days*)

Revia®* (naltrexone oral)

Suboxone® (buprenorphine with naloxone): 2 mg/0.5 mg and 8 mg/2 mg tablet
 Subutex® (buprenorphine): 2 mg and 8 mg tablets

Constipation: Chronic or IBS-C

*Length of Authorization: 3 months
 Quantity limits apply*

NO PA REQUIRED**Bulk-Producing Laxatives**

PSYLLIUM†

Osmotic Laxatives

LACTULOSE†
 POLYETHYLENE GLYCOL 3350 (PEG)† (compare to Miralax®)

PA REQUIRED

Amitiza® (lubiprostone) (*Qty Limit = 2 capsules/day*)

Contraceptives: Vaginal Ring

Length of Authorization: n/a

NO PA REQUIRED

NUVARING® (etonogestrel/ethinyl estradiol vaginal ring)

PA REQUIRED**Coronary Vasodilators/Antianginals: Oral**

*Length of Authorization: 3 years
 Quantity limits apply*

NO PA REQUIRED

ISOSORBIDE DINITRATE† tablet (compare to Isordil®)
 ISOSORBIDE DINITRATE† SL tablet
 ISOSORBIDE DINITRATE† ER tablet
 ISOSORBIDE MONONITRATE† tablet (compare to Ismo®, Monoket®)
 ISOSORBIDE MONONITRATE† ER tablet (compare to Imdur®)
 NITROGLYCERIN† SL tablet
 NITROGLYCERIN† ER capsule
 NITROLINGUAL PUMP SPRAY®
 NITROGARD® BUCCAL
 NITROQUICK® (nitroglycerin SL tablet)
 NITROSTAT® (nitroglycerin SL tablet)
 NITRO-TIME® (nitroglycerin ER capsule)

PA REQUIRED

Dilatrate-SR® (isosorbide dinitrate SR capsule)
 Imdur®* (isosorbide mononitrate ER tablet)
 Ismo®* (isosorbide mononitrate tablet)
 Isordil®* (isosorbide dinitrate tablet)
 Monoket®* (isosorbide mononitrate tablet)

BiDil® (isosorbide dinitrate/hydralazine)

Ranexa® (ranolazine) (*Quantity Limit = 3 tablets/day (500 mg), 2 tablets/day (1000 mg)*)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Coronary Vasodilators/Antianginals: Topical

Length of Authorization: 3 years

NO PA REQUIRED

NITREK[®] (nitroglycerin transdermal patch)
NITRO-BID[®] (nitroglycerin ointment)
NITROGLYCERIN TRANSDERMAL PATCHES† (compare to Nitro-Dur[®])

PA REQUIRED

Nitro-Dur^{®*} (nitroglycerin transdermal patch)

Cough and Cold Preparations

Length of Authorization: for date of service, no refills

Effective May 1, 2008 PA required for Age < 2 years old for all cough and cold (brand and generic)

NO PA REQUIRED

All generics
MUCINEX[®] (guaifenesin)

PA REQUIRED

Tussionex[®] (hydrocodone/chlorpheniramine) (*Quantity Limit = 60 ml*)
All other brands

Dermatological Agents: Genital Wart Therapy

Length of Authorization: Up to 16 weeks

Quantity limits apply

NO PA REQUIRED

ALDARA[®] (imiquimod)

PODOFILOX SOLUTION† (compare to Condylox[®])

PA REQUIRED

Condylox[®] Gel (podofilox gel)
Condylox^{®*} solution (podofilox solution)

Veregan[®] (sinecatechins ointment)
(*Quantity limit = 15 grams (1 tube)/per 30 days*)

Dermatological Agents: Scabicides and Pediculocides

Length of Authorization: date of service only, no refills

NO PA REQUIRED

EURAX[®] (crotamiton) *C, L*
NIX[®] (permethrin) *CR, G, Sp*
permethrin† (compare to Elimite[®]) *C*
permethrin† *L*
piperonyl butoxide and pyrethrins† *G, S, Sh*
RID[®] (piperonyl butoxide and pyrethrins) *G, Sh, Sp*

All other brand and generic Scabicides and Pediculocides

PA REQUIRED

Elimite^{®*} (permethrin 5 %) *C*
Lindane† *L, Sh*
Ovide[®] (malathion) *L*

C=cream, CR=crème rinse, G=gel, L=lotion, S=solution, Sh=shampoo, Sp=spray

Desmopressin: Intranasal

Length of Authorization: 2 years

NO PA REQUIRED

PA REQUIRED

DDAVP[®] (desmopressin) Nasal Solution or Spray 0.01%
Desmopressin † Nasal Solution or Spray 0.01 % (compare to DDAVP[®])
Mimirin † (desmopressin) Nasal Spray 0.01%
Stimate[®] (desmopressin) Nasal Solution 1.5 mg/ml

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Diabetic Testing Supplies

Length of Authorization: 5 years

NO PA REQUIRED

DIABETIC MONITORS/METERS

FREESTYLE LITE[®] SYSTEM KIT
FREESTYLE FLASH[®] SYSTEM KIT
FREESTYLE FREEDOM[®] SYSTEM KIT
FREESTYLE FREEDOM LITE[®] SYSTEM KIT
ONE TOUCH[®] ULTRA 2 KIT
ONE TOUCH[®] ULTRA MINI KIT
ONE TOUCH[®] ULTRA SMART KIT
PRECISION XTRA[®] METER

DIABETIC TEST STRIPS

FREESTYLE^{®*}
FREESTYLE LITE^{®*}
ONE TOUCH[®] BASIC*
ONE TOUCH[®] SURESTEP*
ONE TOUCH[®] FAST TAKE*
ONE TOUCH[®] UL[®]TRA*
PRECISION XTRA^{®*}
PRECISION XTRA[®] BETA KETONE (10 count)

* 50 and 100 count package sizes

PA REQUIRED

Accucheck[®]
Ascensia[®]
Assure[®]
Exactech[®]
Prodigy[®]

All other brands and store brands

Accucheck[®]
Ascensia[®]
Assure[®]
Exactech[®]
Prodigy[®]

All other brands and store brands

Gastrointestinal: Crohn's Disease Injectables

Length of Authorization: Initial PA 3 months; 12 months thereafter

Therapy-specific PA fax form available on OVHA website.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

CIMZIA[®] (certolizumab pegol)
HUMIRA[®] (adalimumab)
REMICADE[®] (infliximab)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Tysabri[®] (natalizumab)

Gastrointestinals: H2-blockers

Length of Authorization: 1 year

NO PA REQUIRED

CIMETIDINE[†] (compare to Tagamet[®]) tablet
FAMOTIDINE[†] (compare to Pepcid[®]) tablet
RANITIDINE[†] (compare to Zantac[®]) tablet

SYRUPS AND SPECIAL DOSAGE FORMS

CIMETIDINE [†] ORAL SOLUTION
ZANTAC[®] (ranitidine) SYRUP

PA REQUIRED

Axid[®] (nizatidine) capsule §
nizatidine[†] (compare to Axid[®]) capsule §
Pepcid^{®*} (famotidine) tablet §
ranitidine[†] capsule §
Tagamet^{®*} tablet §
Zantac^{®*} tablet §

Axid[®] (nizatidine) Oral Solution §
Pepcid[®] Oral Suspension §
ranitidine[†] syrup §
Zantac Effervescent[®] §

PDL Key:

[†] Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Gastrointestinals: Inflammatory Bowel Agents (Oral and Rectal Products)

Length of Authorization: 1 year

NO PA REQUIRED

Mesalamine Products

ASACOL[®] (mesalamine tablet delayed-release)
CANASA[®] (mesalamine suppository)
LIALDA[®] (mesalamine tablet extended-release)
MESALAMINE ENEMA† (compare to Rowasa[®])
PENTASA[®] (mesalamine cap CR)

Other

BALSALAZIDE† (compare to Colazal[®])
DIPENTUM[®] (olsalazine)
SULFASALAZINE† (compare to Azulfidine[®])

PA REQUIRED

Rowasa^{®*} (mesalamine enema)

Azulfidine^{®*} (sulfasalazine)
Colazal^{®*} (balsalazine)

Gastrointestinals: Proton Pump Inhibitors

Length of Authorization: up to 1 year

Quantity limits apply

♣ No PA required for patients <16 years; Quantity Limits still apply.

♠ No PA required for patients < 12 years; Quantity Limits still apply.

NO PA REQUIRED FOR ONCE DAILY DOSES

ORAL CAPULES/TABLETS

PREVACID[®] (lansoprazole) capsules (*Quantity limit=1 cap/day*)
PRILOSEC OTC[®] 20mg (omeprazole magnesium) tablets
(*No Quantity limit applies*)
PROTONIX[®] (pantoprazole) tablets (*Quantity limit=1 tab/day*)

SUSPENSION & SPECIAL DOSAGE FORMS

PREVACID[®] (lansoprazole) packets (*Quantity limit=1 packet/day*)
PREVACID SOLUTABS^{®*} (lansoprazole) (*Quantity limit=1 tab/day*)

COMBINATION (H.Pylori eradication)

Prevpac[®] (lansoprazole w/ H.pylori anti-bacterials) (*No Quantity limit applies*)

PA REQUIRED

Aciphex[®] (rabeprazole) tablets § (*Quantity limit=1 tab/day*)
Nexium[®] (esomeprazole) capsules § (*Quantity limit=1 cap/day*)
omeprazole †* generic RX capsules § (*Quantity limit=1 cap/day*)
omeprazole †* generic OTC tablets § (*Quantity limit=1 tab/day*)
pantoprazole † generic tablets (*Quantity limit=1 tab/day*)
Prilosec[®] (brand) capsules § (*Quantity limit=1 cap/day*)
Zegerid[®] (omeprazole) capsules § (*Quantity limit=1 cap/day*)

Nexium[®] (esomeprazole) powder for suspension §
(*Quantity limit=1 packet/day*)
Protonix[®] (pantoprazole) packet (*Quantity limit=1 packet/day*)
Zegerid^{®*} (omeprazole) powder for suspension §
(*Quantity limit=1 packet/day*)

Gastrointestinal: Ulcerative Colitis Injectables

Length of Authorization: Initial PA 3 months; 12 months thereafter

Therapy-specific PA fax form available on OVHA website.

NO PA REQUIRED

PA REQUIRED

Remicade[®] (infliximab)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Glucocorticoids: Topical

Length of Authorization: duration of prescription, up to 6 months.

NO PA REQUIRED

ALCLOMETASONE† (compare to Aclovate®)
DESONIDE† (compare to Tridesilon®)
FLUOCINOLONE 0.01%† (compare to Synalar®)
HYDROCORTISONE ACETATE† (all generics)

PA REQUIRED

Low Potency

Aclovate®*
Cortaid®*
Desonate® gel (desonide)
DesOwen®*
Hytone®*
Nucort®
Synalar® 0.01%* (all products)
Tridesilon®*
Verdeso® (desonide foam)
All other brands

Medium Potency

BECLOMETHASONE DIPROPIONATE† (compare to Alphatrex®)
BETAMETHASONE VALERATE† (compare to Beta-Val®)
DESOXIMETASONE 0.05%† (compare to Topicort®)
FLUOCINOLONE 0.025%† (compare to Synalar®)
FLUTICASONE TOPICAL† (compare to Cutivate®)
HYDROCORTISONE BUTYRATE† (compare to Locoid®)
HYDROCORTISONE VALERATE† (compare to Westcort®)
MOMETASONE FUROATE† (compare to Elocon®)
TRIAMCINOLONE ACETONIDE† (compare to Aristocort®)

Alphatrex®*
Aristocort®* (all products)
Beta-Val®*
Cloderm® (clocortolone)
Cordran®* (all products)
Cutivate®*
Dermatop®
Elocon®* (all products)
Kenalog® (all products)
Locoid®
Luxiq®
prednicarbate† (compare to Dermatop®)
Pandel®
Synalar® 0.025%* (all products)
Topicort® 0.05%* (all products)
Westcort®* (all products)
All other brands

High Potency

AMCINONIDE† (compare to Cyclocort®)
AUGMENTED BETHAMETHASONE CREAM† (compare to Diprolene® AF)
DESOXIMETASONE 0.25%† (compare to Topicort®)
DIFLORASONE DIACETATE† (compare to Apexicon®, Maxiflor®, Psorcon-E®)
FLUOCINOLONE 0.2%† (compare to Synalar®)
FLUOCINONIDE† (compare to Lidex®)

Apexicon®*
Cyclocort®*
Diprolene® AF* (all products)
Halog®* (all products)
Lidex®* (all products)
Maxiflor®*
Synalar® 0.2%* (all products)
Topicort® 0.25%* (all products)
Vanos®
All other brands

Very High Potency

AUGMENTED BETHAMETHASONE OINTMENT† (compare to Diprolene®)
CLOBETASOL PROPIONATE† (compare to Temovate®)
CLOBETASOL PROPIONATE† FOAM (compare to Olux®)
DIFLORASONE DIACETATE EMOLL† (compare to Psorcon®)
HALOBETASOL PROPIONATE† (compare to Ultravate®)

Clobex®
Cormax®
Diprolene®* (all products)
Embeline E®*
Olux®/Olux E®
Psorcon®*
Temovate®* (all products)
Ultravate®* (all products)
All other brands

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Growth Stimulating Agents

Length of Authorization: 6 months initially, then up to 1 year; short bowel syndrome = 4 weeks.

Agents available after clinical criteria are met.

****Must be obtained through Specialty Pharmacy Provider, ICORE****

Therapy specific PA form/order form is available on OVHA website.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

NORDITROPIN[®]
NUTROPIN[®]/NUTROPIN[®] AQ

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Genotropin[®]
Humatrope[®]
Omnitrope[®]
Saizen[®]
Tev-Tropin[®]

Specialized Indications – See Specific Criteria

Increlex[®] (mecasermin)
Serostim[®]
Zorbtive[®]

Hemophilia Factors

****Must be obtained through Specialty Pharmacy Provider, ICORE****

Therapy specific Order form is available on OVHA website.

NO PA REQUIRED

All Factors

PA REQUIRED

None

Hepatitis C Agents

Length of Authorization: 6 months

Quantity limits apply

****Must be obtained through Specialty Pharmacy Provider, ICORE****

Therapy specific PA form/order form is available on OVHA website.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

RIBAVIRIN

Tablets/Capsules

RIBAVIRIN† 200 mg tablets or capsules

Oral Solution

INTERFERON

PEGASYS[®] (peg-interferon alpha 2-a) (QL = 4 vials/28 days)

PEGASYS CONVENIENCE PACK[®] (peg-interferon alfa-2a) (QL = 1 kit/28 days)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

RIBAVIRIN

Copegus[®] (ribavirin 200 mg tablet)

Ribapak[®] 400 mg/600 mg Dose Pack (ribavirin)

Rebetol[®] (ribavirin 200 mg capsule)

All other strengths/brands of ribavirin tablets/capsules

Rebetol[®] (ribavirin 40 mg/ml) oral solution

INTERFERON

Infergen[®] (interferon alphacon-1)

Peg-Intron[®] (peg-interferon alpha-2b)

Immunomodulators: Topical

****Caution not approved for use in children under 2 years old****

Effective 11/1/06: PA required for Elidel / Protopic for children < 2 years. Quantity Limit = 30 gm / fill, 90 gm / 6 mos. Step Therapy required (previous trial of topical steroid for patients ≥ 2 yrs). Protopic ointment concentration limited to 0.03% for age < 16 years old.

NO PA REQUIRED

ELIDEL[®] (pimecrolimus) §
PROTOPIC[®] (tacrolimus) §

PA REQUIRED

Elidel[®] (age < 2 yrs)
Protopic[®] (age < 2 yrs)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Lipotropics: Bile Acid Sequestrants

Length of Authorization: lifetime

NO PA REQUIRED

CHOLESTYRAMINE† powder (compare to Questran®)
CHOLESTYRAMINE LIGHT† powder (compare to Questran Light®)
PREVALITE† powder (cholestyramine light)

COLESTIPOL† tablets, granules (compare to Colestid®)

PA REQUIRED

Questran® powder (cholestyramine)
Questran Light® powder (cholestyramine light)

Colestid®* tablets, granules (colestipol)
Welchol® (colesevelam)

Lipotropics: Fibric Acid Derivatives

Length of Authorization: 3 months initially, then 1 year if response shown

NO PA REQUIRED

GEMFIBROZIL† (compare to Lopid®) 600 mg
♦TRICOR® (fenofibrate) § 48 mg, 145 mg

♦ *PA required if patient not on concurrent statin*

PA REQUIRED

Antara® (fenofibrate micronized) § 43 mg, 130 mg
fenofibrate† § 54 mg
fenofibrate micronized† § 67 mg, 134 mg, 200 mg
Fenoglide® (fenofibrate) § 40 mg, 120 mg
Lipofen® (fenofibrate) § 50 mg, 150 mg
Lofibra® (fenofibrate micronized) Capsules § 67mg, 134 mg, 200 mg
Lofibra® (fenofibrate) Tablets § 54 mg, 160 mg
Lopid®* (gemfibrozil) § 600 mg
Triglide® (fenofibrate) § 50 mg, 160 mg

Lipotropics: Niacin Derivatives

Length of Authorization: n/a

NO PA REQUIRED

NIACIN†
NIASPAN® (niacin)
NIASPAN® ER (niacin)

PA REQUIRED

Lipotropics: Statins

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

LOVASTATIN† (compare to Mevacor®) (*QL = 1 tablet/day (10 & 20 mg), 2 tabs/day (40 mg)*)
PRAVASTATIN† (compare to Pravachol®) (*QL = 1 tablet/day (10 & 20 mg), 2 tabs/day (40 mg)*)

SIMVASTATIN† (compare to Zocor) (*QL = 1 tablet/day*)

AFTER GENERIC SIMVASTATIN TRIAL

CRESTOR® (rosuvastatin calcium) §
(*QL = 1 tablet/day*)

PA REQUIRED

Low/Medium Potency Statins

Altoprev® (aka: Altocor®) (lovastatin) (*QL = 1 tablet/day*)
Lescol® (fluvastatin) (*QL = 1 tablet/day*)
Lescol® XL (fluvastatin XL) (*QL = 1 tablet/day*)
Mevacor®* (lovastatin) (*QL = 1 tab/day (10 & 20 mg), 2 tabs/day (40 mg)*)
Pravachol®* (pravastatin) (*QL = 1 tab/day (10 & 20 mg), 2 tabs/day (40 mg)*)
Pravastatin † 80 mg Tablet (use 40 mg tablets)

High Potency Statins

Lipitor® (atorvastatin) (*QL = 1 tablet/day*)
Zocor®* (◻imvastatin) (*QL = 1 tablet/day*)

PDL Key:

† **Generic product**

* **Indicates a generic equivalent is available without PA**

§ **Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)**

Lipotropics: Miscellaneous/Combinations*Length of Authorization: 1 year**Quantity limits apply*

NO PA REQUIRED

PA REQUIRED

Miscellaneous

Lovaza® (omega-3-acid ethyl esters)

Cholesterol Absorption Inhibitors/CombinationsZETIA® (ezetimibe) § (AFTER CLINICAL CRITERIA ARE MET)
(Qty Limit = 1 tablet/day)

Vytorin® (ezetimibe/simvastatin) (QL = 1 tablet/day)

Other Statin CombinationsADVICOR® (lovastatin/niacin) (Qty Limit = 1 tablet/day)
SIMCOR® (simvastatin/extended release niacin) (Qty Limit = 1
tablet/day)

Caduet® (atorvastatin/amlodipine) (Qty Limit = 1 tablet/day)

Miscellaneous: Arcalyst® (CAPS Injectable)*Length of Authorization: 1 year**Quantity limits apply*

NO PA REQUIRED

PA REQUIRED

Arcalyst® (rilonacept) (QL = 2 vials for loading dose, then 1 vial per week)

Miscellaneous: Elaprase® (Hunter's Syndrome Injectable)*Length of Authorization: 1 year**Quantity limits apply*****Must be obtained through Specialty Pharmacy Provider, ICORE****

NO PA REQUIRED

PA REQUIRED

Elaprase® (idursulfase) (QL = calculated dose/week)

Miscellaneous: Soliris® (Paroxysmal Nocturnal Hemoglobinuria Injectable)*Length of Authorization: Initial 3 months, Subsequent 1 year**Quantity limits apply*

NO PA REQUIRED

PA REQUIRED

Soliris® (eculizumab) (Quantity Limit = 20 vials total/3 months initially; 6
vials/month subsequently)**Miscellaneous: Somatuline® (Acromegaly Injectable)***Length of Authorization: Initial 3 months, Subsequent 1 year**Quantity limits apply*

NO PA REQUIRED

PA REQUIRED

Somatuline® Depot Injection (lanreotide) (Quantity Limit = 0.2 ml/28 days (60
mg syringe), 0.3 ml/28 days (90 mg syringe) and 0.5 ml/28 days (120 mg
syringe))**Mood Stabilizers (see also Anticonvulsants)***Length of Authorization: duration of need*

NO PA REQUIRED

PA REQUIRED

EQUETRO® (carbamazepine)
LITHIUM CARBONATE† (compare to Eskalith®)
LITHIUM CARBONATE SR† (compare to Eskalith CR®, Lithobid®)
LITHIUM CITRATE SYRUP†Eskalith CR®* (lithium carbonate SR)
Lithobid®* (lithium carbonate SR)**PDL Key:**

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy
automatically screened for upon claims processing)

Multiple Sclerosis: Injectables

Length of Authorization: Initial PA 3 months; 12 months thereafter

Quantity limits apply

****Self-injectables (Avonex[®], Betaseron[®], Rebif[®] and Copaxone[®]) must be obtained through Specialty Pharmacy Provider, ICORE****

NO PA REQUIRED

Interferons

AVONEX[®] (interferon B-1a)

BETASERON[®] (interferon B-1b)

REBIF[®] (interferon B-1a)

Other

COPAXONE[®] (glatiramer acetate) (QL = 1 kit/30 days)

PA REQUIRED

Tysabri[®] (natalizumab)

Nutritionals, liquid oral supplements

Length of Authorization: 6 months

Therapy specific PA fax form available on OVHA website.

NO PA REQUIRED

PA REQUIRED

PA applies to oral (swallowed) liquid nutrition: Contact MedMetrics.

For enteral nutrition (tube feedings), billed via the Medical Benefit, see the following guidelines:
http://ovha.vermont.gov/forproviders/copy_of_GOC13.pdf

Ophthalmics: Antihistamines

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

KETOTIFEN[†] 0.025 % (eg. Alaway[®], Zaditor[®] OTC, others)
(Quantity Limit = 1 bottle/month)

After trial of ketotifen 0.025 %

ELESTAT[®] (epinastine) (Quantity Limit = 1 bottle/month)

PATADAY[®] (olopatadine 0.2 %)/PATANOL[®] (olopatadine 0.1%)
(Quantity Limit = 1 bottle/month)

PA REQUIRED

Emadine[®] (emedastine) (Quantity Limit = 2 bottles/month)

Optivar[®] (azelastine) (Quantity Limit = 1 bottle/month)

Zaditor[®] RX (ketotifen 0.025 %) (Quantity Limit = 1 bottle/month)

PDL Key:

[†] Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Ophthalmics: Glaucoma Agents/Miotics

Length of Authorization: lifetime

NO PA REQUIRED

ALPHA-2 ADRENERGIC

Single Agent

ALPHAGAN[®] P (brimonidine tartrate)
BRIMONIDINE TARTARATE† (compare to Alphagan[®])

Combination

COMBIGAN[®] (brimonidine tartrate/timolol maleate)

BETA BLOCKER

BETAXOLOL HCl† (compare to Betoptic[®])
BETOPTIC S[®] (betaxolol suspension)
CARTEOLOL HCl† (compare to Ocupress[®])
LEVOBUNOLOL HCl† (compare to AKBeta[®], Betagan[®])
METIPRANOLOL† (compare to Optipranolol[®])
TIMOLOL MALEATE† (compare to Istalol[®], Timoptic[®])

PROSTAGLANDIN INHIBITORS

Note: Coverage of a 'preferred' PI agent is contingent upon a 1st-line trial of any other preferred beta-blocker, a-2 adrenergic or CAI agent. Coverage of a 'non-preferred' PI agent is contingent upon a similar first-line trial as well as a failed trial of both preferred PI products.

LUMIGAN[®] (bimatoprost) §
TRAVATAN[®]/TRAVATAN Z[®] (travoprost) §

CARBONIC ANHYDRASE INHIBITOR

Single Agent

DORZOLAMIDE 2 % (compare to Trusopt[®])

Combination

DORZOLAMIDE w/TIMOLOL (compare to Cosopt[®])

MISCELLANEOUS

DIPIVEFRIN HCl† (compare to AKPro[®], Propine[®])
EPINEPHRINE† (compare to Epifrin[®], Glaucon^{®*})
ISOPTO[®] CARBACHOL (carbachol)
ISOPTO[®] CARPINE (pilocarpine)
PILOCARPINE HCl† (compare to Pilocar[®])
PILOPINE[®] (pilocarpine)
PHOSPHOLINE IODIDE[®] (echothiophate)

PA REQUIRED

Iopidine[®] (apraclonidine) - *no PA required for pts <=10yrs*

Betagan^{®*}
Betimol^{®*}
Istalol^{®*}
Optipranolol^{®*}
Timoptic^{®*}
Timoptic XE^{®*}

Xalatan[®] (latanoprost)

Azopt[®] (brinzolamide 1%)
Trusopt^{®*} (dorzolamide 2 %)

Cosopt^{®*} (dorzolamide w/timolol)

Miochol-E[®]
Miostat[®]
Pilocar^{®*}
Propine^{®*}

Ophthalmics: Mast Cell Stabilizers

Length of Authorization: 6 months

NO PA REQUIRED

ALAMAST[®] (pemirolast potassium)
CROMOLYN SODIUM† (compare to Crolo[®], Opticrom[®])

PA REQUIRED

Alocril[®] (nedocromil sodium)
Alomide[®] (iodoxamide)
Crolo^{®*}

Ophthalmics: Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

Length of Authorization: 1 year

NO PA REQUIRED

ACULAR[®] (ketorolac 0.5% ophthalmic sol.)
ACULAR LS[®] (ketorolac 0.4% ophthalmic sol.)
ACULAR[®] PF (ketorolac 0.5% ophthalmic sol.)
FLURBIPROFEN † 0.03% ophthalmic sol.

PA REQUIRED

Diclofenac† 0.1% ophthalmic sol (compare to Voltaren[®])
Nevanac[®] ophthalmic susp. (nepafenac 0.1%)
Xibrom[®] ophthalmic sol. (bromfenac 0.09%)
Ocufen^{®*} ophthalmic sol. (flurbiprofen 0.03%)
Voltaren[®] (diclofenac 0.1% ophthalmic sol.)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Ophthalmics: Quinolone Anti-infectives

Length of Authorization: duration of therapy requested

NO PA REQUIRED

CIPROFLOXACIN HCl† (compare to Ciloxan®)
OFLOXACIN† (compare to Ocuflox®)

PA REQUIRED

Ciloxan®*
Iquix® (levofloxacin 1.5%) (preservative free)
Ocuflox®*
Quixin® (levofloxacin 0.5%)
Vigamox® (moxifloxacin) (preservative free)
Zymar® (gatifloxacin)

Ossification Enhancers

Length of Authorization: lifetime

Quantity limits apply

Therapy-specific PA fax form for Injectable Bisphosphonates available on OVHA website.

NO PA REQUIRED

ORAL BISPHOSPHONATES

BONIVA® (ibandronate) 150 mg (*Quantity Limit = 1 tab/28 days*)
BONIVA® (ibandronate) 2.5 mg *No quantity limits*
FOSAMAX® (alendronate)
FOSAMAX PLUS D® (alendronate/vitamin D)

INJECTABLE BISPHOSPHONATES

MIACALCIN® (calcitonin)

PA REQUIRED

Actonel® (risedronate)
Actonel® w/calcium (risedronate/calcium)
Alendronate† (compare to Fosamax®)
Didronel® (etidronate)
Etidronate† (compare to Didronel®)
Skelid® (tiludronate)

Boniva® Injection (ibandronate) (*Quantity Limit = 3 mg/3 months (four doses)/year*)
Reclast® Injection (zoledronic acid) (*Quantity Limit = 5 mg (one dose)/year*)

Fortical® (calcitonin)

Forteo® (teriparatide) (*Quantity Limit = 1 pen (3 ml)/28 days*)

Otic: Anti-Infectives

Length of Authorization: 1 year

NO PA REQUIRED

CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%; otic susp.)
FLOXIN® (ofloxacin 0.3%; otic soln.)
NEOMYCIN/POLYMYXIN B SULFATE/HYDROCORTISONE †

PA REQUIRED

Cipro-HC® (ciprofloxacin 0.2%/hydrocortisone 1%; otic susp.)
Ofloxacin† 0.3 % otic solution
Coly-Mycin S®/Cortisporin TC®
(neomycin/colistin/thonzium/hydrocortisone)
Cortisporin otic®/Pediotic®* (neomycin/polymyxin B sulfate /hydrocortisone)
otic solution/sus

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Parkinson's: Non-Ergot Dopamine Receptor Agonist

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

DOPAMINE PRECURSOR

CARBIDOPA/LEVODOPA† (compare to Sinemet®)
CARBIDOPA/LEVODOPA† ER (compare to Sinemet® CR)
CARBIDOPA/LEVODOPA† ODT (compare to Parcopa®)

DOPAMINE AGONISTS (ORAL)

BROMOCRIPTINE† (compare to Parlodel®)
MIRAPEX® (pramipexole)
ROPINIROLE† (compare to Requip®)

DOPAMINE AGONISTS (TRANSDERMAL)

COMT INHIBITORS

TASMAR® (tolcapone)
COMTAN® (entacapone)

MAO-B INHIBITORS

SELEGILINE† (compare to Eldepryl®)

OTHER

AMANTADINE† (compare to Symmetrel®)
STALEVO® (carbidopa/levodopa/entacapone)

PA REQUIRED

Parcopa®* (carbidopa/levodopa ODT)
Sinemet®* (carbidopa/levodopa)
Sinemet CR®* (carbidopa/levodopa ER)

Parlodel® (bromocriptine)
Requip®* (ropinirole)

Neupro® Patch (rotigotine transdermal) (QL = 1 patch/day)

Azilect® (rasagiline) (QL = 1 mg/day)
Eldepryl® (selegiline)
Zelapar® (selegiline ODT) (QL = 2.5 mg/day)

Symmetrel® (amantadine)

Phosphodiesterase-5 (PDE-5) Inhibitors

Length of Authorization: 1 year

Quantity limits apply

Effective 7/1/06, phosphodiesterase-5 (PDE-5) inhibitors are no longer a covered benefit for all Vermont Pharmacy Programs for the treatment of erectile dysfunction. This change is resultant from changes set into effect January 1, 2006 and as detailed in Section 1903 (i)(21)(K) of the Social Security Act (the Act), precluding Medicaid Federal Funding for outpatient drugs used for the treatment of sexual or erectile dysfunction. Sildenafil will remain available for coverage via prior-authorization for the treatment of Pulmonary Arterial Hypertension.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Revatio® (sildenafil) (Quantity Limit = 3 tabs/day)
Viagra® (sildenafil) (Quantity Limit = 3 tabs/day)

Platelet Inhibitors

Length of Authorization: 3 years

NO PA REQUIRED

AGGREGATION INHIBITORS

CLOSTAZOL† (compare to Pletal®)
CLOPIDOGREL† (compare to Plavix®)
PLAVIX® (clopidogrel bisulfate)
TICLOPIDINE† (compare to Ticlid®)

OTHER

ASPIRIN†
DIPYRIDAMOLE† (compare to Persantine®)

PA REQUIRED

Pletal®*
Ticlid®*

Aggrenox® (dipyridamole/ASA)
Persantine®*

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Psoriasis Injectables

Length of Authorization: initial PA of 3 months, 12 months thereafter.

Quantity limits apply

Therapy-specific PA fax form available on OVHA website.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

ENBREL® (etanercept)
HUMIRA® (adalimumab)
RAPTIVA® (efalizumab)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Amevive® (alefacept)
Remicade® (infliximab)

Psoriasis: Non-Biologics

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

CYCLOSPORINE † (all brand and generic)
METHOTREXATE † (all brand and generic)
OXSORALEN-ULTRA® (methoxsalen)
SORIATANE® CK (acitretin)

CALCIPOTRIENE † Solution (compare to Dovonex®)
DOVONEX® (calcipotriene cream/ointment)
PSORiatec®, DRITHO-SCALP® (anthralin cream)
TAZORAC® (tazarotene cream, gel)

PA REQUIRED

Oral

Topical

Dovonex®* solution (calcipotriene)
Taclonex® (calcipotriene/betamethasone ointment/scalp suspension)
(QL for initial fill = 60 grams)

Pulmonary: Anticholinergics, Inhaled

Length of Authorization: 1 year

NO PA REQUIRED

METERED DOSE INHALER (SINGLE AGENT)

ATROVENT HFA® (ipratropium)
SPIRIVA® (tiotropium)

NEBULIZER (SINGLE AGENT)

IPRATROPIUM SOLN FOR INHALATION

METERED DOSE INHALER (COMBINATION PRODUCT)

COMBIVENT® (ipratropium/albuterol)

NEBULIZER (COMBINATION PRODUCT)

IPRATROPIUM/ALBUTEROL † (compare to Duoneb®)

PA REQUIRED

Duoneb®* (ipratropium/albuterol)

Pulmonary: Antihistamines - Intranasal

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

PA REQUIRED

Astelin® (azelastine) Nasal Spray
Quantity Limit = 1 bottle (30 ml)/25 days

Patanase® (olopatadine 0.6%) Nasal Spray
Quantity Limit = 1 bottle (31 gm)/30 days

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Pulmonary: Antihistamines-1st Generation

Length of Authorization: 1 year

NO PA REQUIRED

All generic antihistamines

All generic antihistamine/decongestant combinations

PA REQUIRED

All brand antihistamines (example: Benadryl®)

All brand antihistamine/decongestant combinations (example: Deconamine SR®, Rynatan®, Ryna-12®)

Pulmonary: Antihistamines-2nd Generation

Length of Authorization: 1 year

NO PA REQUIRED

LORATADINE (OTC) † (compare to Claritin®)

CETIRIZINE † OTC (compare to Zyrtec® OTC)

FEXOFENADINE † (after loratadine OTC and cetirizine OTC trials)

LORATADINE-D (OTC) †

LORATADINE (OTC) † syrup

CETIRIZINE † (OTC) syrup

ZYRTEC® OTC (cetirizine) SYRUP

LORATADINE (OTC) † rapidly disintegrating tablet (RDT)

PA REQUIRED

Allegra® (fexofenadine)

Clarinex® (desloratadine)

Claritin® (loratadine)

Xyzal® (levocetirizine)

Zyrtec® RX/OTC* (cetirizine)

Allegra-D® § (12 HR & 24 HR)

Cetirizine-D † SR

Clarinex-D® § (12 HR & 24 HR)

Claritin-D® §

Zyrtec-D® §

Allegra® suspension

Clarinex® Syrup

Claritin Syrup**

Xyzal (levocetirizine) Syrup®

Zyrtec RX Syrup®

Allegra ODT® §

Cetirizine † Chewable Tablets

Clarinex Reditabs® §

Claritin Chewable Tablets® §

Claritin Reditabs®*§

Zyrtec® Chewable Tablets §

Pulmonary: Persistent Asthma

Length of Authorization: 3 months after clinical criteria are met.

Therapy specific clinical criteria are available on the OVHA website.

NO PA REQUIRED

PA REQUIRED

Xolair® (omalizumab)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Pulmonary: Beta-adrenergic Agents

Length of Authorization: 5 years

Quantity limits apply

Effective 11/1/06: Albuterol Sulfate MDI moves to "PA REQUIRED" (existing users of this product will maintain coverage without prior authorization indefinitely via grandfathering provisions)

NO PA REQUIRED

METERED-DOSE INHALERS (SHORT-ACTING)

XOPENEX[®] HFA (levalbuterol)

METERED-DOSE INHALERS (LONG-ACTING)

FORADIL[®] (formoterol) (after criteria for LABA are met)
SEREVENT[®] DISKUS (salmeterol xinafoate) (after criteria for LABA are met)

NEBULIZER SOLUTIONS (SHORT-ACTING)

ACCUNEB[®] (albuterol sulfate solution 0.63 mg/ml and 1.25 mg/ml)
ALBUTEROL 0.83 mg/ml neb solution †
METAPROTERENOL † neb solution
XOPENEX[®] neb solution (levalbuterol HCL) (age ≤ 12 yrs)

NEBULIZER SOLUTIONS (LONG-ACTING)

TABLETS/SYRUP (SHORT-ACTING)

TERBUTALINE † tablets (compare to Brethine[®])
ALBUTEROL † tablets/syrup
METAPROTERENOL † tablets/syrup

TABLETS (LONG-ACTING)

ALBUTEROL ER † tablets

PA REQUIRED

♣ albuterol MDI †
Alupent[®] (metaproterenol)
Maxair[®] Autohaler (pirbuterol)
♣ Proair[®] (albuterol)
♣ Proventil[®] HFA (albuterol)
♣ Ventolin[®] HFA (albuterol)

♣ coverage grandfathered for current users

albuterol sulfate solution † 0.63 mg/ml and 1.25 mg/ml (compare to Accuneb[®])

Xopenex[®] neb solution (age > 12 yrs)

Brovana[®] (arformoterol) QL = 2 vial/day
Perforomist[®] (formoterol) QL = 2 vial/day

Brethine[®]* (terbutaline)

Vospire ER[®]* (albuterol)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Pulmonary: Inhaled Glucocorticoids/Glucocorticoid Combinations

Length of Authorization: 5 years

Quantity limits apply

NO PA REQUIRED

METERED DOSE INHALERS (SINGLE AGENT)

ASMANEX[®] 220 mcg/inh (mometasone furoate) ((*QL* = 0.72 gm (3 inhalers)/90 days))

ASMANEX[®] 110 mcg/inh (mometasone furoate) ((*QL* = 0.405 gm (3 inhalers)/90 days))

AZMACORT[®] (triamcinolone acetonide)

FLOVENT[®] DISKUS (fluticasone propionate)

FLOVENT[®] HFA (fluticasone propionate) (*QL* = 36 gm(3 inhalers)/90 days)

PULMICORT Flexhaler[®] (budesonide)

METERED DOSE INHALERS (COMBINATION PRODUCT)

ADVAIR[®] DISKUS (fluticasone/salmeterol)

ADVAIR[®] HFA (fluticasone/salmeterol)

SYMBICORT[®] (budesonide/formoterol) (*QL* = 30.6 gm (3 inhalers)/90 days)

NEBULIZER SOLUTIONS

PULMICORT RESPULES[®] (budesonide) (age ≤ 12 yrs)

PA REQUIRED

AeroBid[®] (flunisolide) §

AeroBid-M[®] §

QVAR[®] (beclomethasone) §

Pulmicort (budesonide) Respules[®] (age > 12 yrs)

Pulmonary: Nasal Glucocorticoids

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

FLUTICASONE Propionate† (compare to Flonase[®])

QL = 16 gm (1 inhaler)/30 days

NASACORT AQ[®] (triamcinolone)

QL = 16.5 gm (1 inhaler)/30 days

NASONEX[®] (mometasone)

QL = 17 gm (1 inhaler)/30 days

PA REQUIRED

Beconase AQ[®] (beclomethasone)

QL = 50 gm (2 inhalers)/30 days

Flonase[®]* (fluticasone propionate)

QL = 16 gm (1 inhaler)/30 days

flunisolide † 25 mcg/spray (previously Nasalide[®])

QL = 50 ml (2 inhalers)/30 days

flunisolide† 29 mcg/spray (compare to Nasarel[®])

QL = 50 ml (2 inhalers)/30 days

Nasarel[®] (flunisolide 29 mcg/spray)

QL = 50 ml (2 inhalers)/30 days

Omnaris[®] (ciclesonide)

QL = 12.5 gm (1 inhaler)/30 days

Rhinocort Aqua[®] (budesonide)

QL = 8.6 gm (1 inhaler)/30 days

Veramyst[®] (fluticasone furoate)

QL = 10 gm (1 inhaler)/30 days

Pulmonary: Systemic Glucocorticoids

Length of Authorization: 1 year

NO PA REQUIRED

CORTISONE ACETATE†

DEXAMETHASONE†

HYDROCORTISONE† (compare to Cortef[®])

METHYLPREDNISOLONE† (compare to Medrol[®])

ORAPRED[®] oral solution/ODT (prednisolone sod phosphate) (age < 12 yrs)

PREDNISOLONE† tabs / liquid (compare to Pediapred[®], Prelone[®])

PREDNISONE†

PA REQUIRED

Celestone[®]

Cortef[®]*

Medrol[®]*

Millipred[®] (prednisolone) oral solution

Orapred[®] oral solution (age ≥ 12 yrs)

Orapred[®] ODT (age ≥ 12 yrs)

Pediapred[®]*

Prelone[®]*

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Pulmonary: Leukotriene Modifiers

Length of Authorization: 1 year

NO PA REQUIRED

ACCOLATE[®] (zafirlukast)
SINGULAIR[®] (montelukast sodium)

PA REQUIRED

ZyFlo[®] (zileuton) §
ZyFlo[®] CR (zileuton SR) §

Pulmonary: RSV Prevention

Length of Authorization: 1 season, 6 doses (November 1-April 30)

Quantity limits apply

****Must be obtained through Specialty Pharmacy Provider, Wilcox Home Infusion****

NO PA REQUIRED

PA REQUIRED: Therapy specific PA fax form is available on the OVHA website

SYNAGIS[®] (palivizumab)

Renal Disease: Phosphate Binders

Length of Authorization: 1 year

NO PA REQUIRED

CALCIUM ACETATE † (compare to Phos Lo[®])
FOSRENOL[®] (lanthanum carbonate)
RENAGEL[®] (sevelamer)

PA REQUIRED

Phos Lo^{®*} (calcium acetate)
Renvela[®] (sevelamer carbonate)

Rheumatoid, Juvenile & Psoriatic Arthritis: Immunomodulators

Length of Authorization: Initial PA of 3 months; 12 months thereafter

Quantity limits apply

Therapy specific PA fax form is available on the OVHA website.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

ENBREL[®] (etanercept)
HUMIRA[®] (adalimumab)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Kineret[®] (anakinra)
Orencia[®] (abatacept)
Remicade[®] (infliximab)

Saliva Stimulants

Length of Authorization: 1 year

NO PA REQUIRED

PILOCARPINE (compare to Salagen[®])
EVOXAC[®] (cevimeline)

PA REQUIRED

Salagen^{®*} (pilocarpine)

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Sedative/Hypnotics

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

ESTAZOLAM† (compare to Prosom®)
FLURAZEPAM† (compare to Dalmane®)
TEMAZEPAM† 15 mg, 30 mg (compare to Restoril®)

PA REQUIRED

Benzodiazepine

Dalmane®* (flurazepam)
Doral® (quazepam)
Halcion® (triazolam)
Prosom®* (estazolam)
Restoril®* (temazepam)
temazepam† 7.5 mg, 22.5 mg (compare to Restoril®)
triazolam† (compare to Halcion®)

Non-benzodiazepine

CHLORAL HYDRATE† syrup, suppository
LUNESTA® (eszopiclone) (Quantity Limit = 1 tab/day)
ZOLPIDEM † (compare to Ambien®)(Quantity Limit = 1 tab/day)

Ambien®* (zolpidem) (Quantity Limit = 1 tab/day)
Ambien CR® (zolpidem) (Quantity Limit = 1 tab/day)
Rozerem® (ramelteon) (Quantity Limit = 1 tab/day)
Somnote® (chloral hydrate capsule)
Sonata® (zaleplon)
Zaleplon †

Skeletal Muscle Relaxants

Length of Authorization: 1 year

Effective 11/1/06: All carisoprodol products (brand and generics) move to "PA REQUIRED"

NO PA REQUIRED

CHLORZOXAZONE† (compare to Parafon Forte DSC®)
CYCLOBENZAPRINE† (compare to Flexeril®)
METHOCARBAMOL† (compare to Robaxin®)
ORPHENADRINE CITRATE ER† (previously Norflex®)
ORPHENADRINE, ASA, CAFFEINE† (previously Norgescic®)

ASA =

PA REQUIRED

Musculoskeletal Agents

Amrix®(cyclobenzaprine sustained-release)
carisoprodol† (compare to Soma®)
carisoprodol, ASA† (compare to Soma Compound®)
carisoprodol, ASA, codeine† (compare to Soma Compound with Codeine®)
Fexmid® (cyclobenzaprine)
Flexeril®* (cyclobenzaprine)
Parafon Forte DSC®* (chlorzoxazone)
Robaxin®* (methocarbamol)
Skelaxin® (metaxalone)
Soma® (carisoprodol)
Soma Compound® (carisoprodol/ASA)
Soma Compound with Codeine® (carisoprodol/ASA/codeine)

Antispasticity Agents

BACLOFEN† (previously Lioresal®)
DANTROLENE† (compare to Dantrium®)
TIZANIDINE† (compare to Zanaflex®) tablets

Dantrium®* (dantrolene)
Zanaflex® (tizanidine) capsules
Zanaflex®* (tizanidine) tablets

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Smoking Cessation Therapies

Length of Authorization: see table

Quantity limits apply (maximum 2 courses per rolling 365 days)

NO PA REQUIRED

NICOTINE REPLACEMENT (maximum duration is 16 weeks (2 x 8 weeks)/365 days)♣

NICODERM CQ PATCH®
NICORETTE GUM®
COMMIT LOZENGE®
NICOTINE LOZENGE†
NICOTROL INHALER®

ORAL THERAPY

BUPROPION SR†
CHANTIX® (varenicline) (Limited to 18 years and older, Quantity Limit = 2 tabs/day, maximum duration 24 weeks (2 x 12 weeks)/365 days)♣

PA REQUIRED

nicotine patch OTC†
nicotine patch RX† (compare to Habitrol®)
Nicotine System Kit®
nicotine gum†
Nicotrol Nasal Spray®

Zyban®* (bupropion SR)
(maximum duration 24 weeks (2 x 12 weeks)/365 days)

♣ For approval of therapy beyond the established maximum duration, the prescriber must provide evidence that the patient is engaged in a smoking cessation counseling program.

Testosterone: Topical

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED

ANDROGEL® GEL
(testosterone 1% gel packets or pump)
*Quantity limit = 2.5 gm packet (1 packet/day)
5 gm packet (2 packets/day)
Pump (4 bottles/30 days)*

PA REQUIRED

Androderm® Transdermal 2.5 mg, 5 mg (testosterone patch) *Quantity limit = 1 patch/day/strength*
Testim® Gel 5 gm (testosterone 1% gel tube)
Quantity limit = 2 tubes/day

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

Urinary Antispasmodics

Length of Authorization: 1 year

Quantity limits apply

NO PA REQUIRED*

SHORT-ACTING AGENTS

OXYBUTYNIN† (compare to Ditropan®)

LONG-ACTING AGENTS (after clinical criteria are met)

Twice Daily Oral (Qty Limit = 2 per day)

SANCTURA® (trospium)

Once Daily Oral (Qty Limit = 1 per day)

ENABLEX® (darifenacin)

OXYBUTYNIN XL† (compare to Ditropan® XL)

SANCTURA XR® (trospium)

VESICARE® (solifenacin)

Transdermal

>NOTE:

- Patients under the age of 65 must fail an adequate trial of generic oxybutinin before approval will be granted for either oxybutynin XL®, Vesicare®, Sanctura®, Sanctura XR® or Enablex®.
- A therapeutic failure on at least two long acting preferred products is required before a PA will be approved on any non-preferred long acting medication..

Recipients < 21 years of age are exempt from all PA Requirements.

(Exception: An adequate trial of oxybutinin/oxybutinin XL will be required before approval of Ditropan®/Ditropan® XL will be granted)

PA REQUIRED

Ditropan®*

Flavoxate † (compare to Urispas®)

Urispas® (flavoxate)

Detrol® (tolterodine)

Detrol LA® (tolterodine LA)

Ditropan XL® (oxybutynin XL)

Oxytrol® (oxybutinin transdermal) (Qty Limit = 8 patches/28 days)

Vaginal Anti-Infectives

Length of Authorization: 1 year

NO PA REQUIRED

CLINDAMYCIN

CLINDAMYCIN VAGINAL† (clindamycin vaginal cream 2%)

CLINDAMAX† (clindamycin vaginal cream 2%)

METRONIDAZOLE

METRONIDAZOLE VAGINAL GEL 0.75%†

VANDAZOLE† (metronidazole vaginal 0.75%)

PA REQUIRED

Cleocin®* (clindamycin vaginal cream 2%)

Clindesse® (clindamycin vaginal cream 2%)

Cleocin® Vaginal Ovules (clindamycin vaginal suppositories)

Metrogel Vaginal®* (metronidazole vaginal gel 0.75%)

Vitamins: Prenatal Multivitamins

Length of Authorization: 1 year

NO PA REQUIRED

All generics

PA REQUIRED

All brands

PDL Key:

† Generic product

* Indicates a generic equivalent is available without PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)